KOL | Hiroshi FujishimaDepartment of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, fujishima117@gmail.com | Department of Ophthalmology, Keio University ... |
kolの履歴書 Hiroshi Fujishima
| Year | |
|---|---|
| 2021 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, Ophthalmology, Tsurumi University Dental Hospital, Yokohama, Kanagawa, Japan |
| 2020 | Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-0016, Japan;, (E.S.);, (N.A.);, (Y.O.) Fujishima Eye Clinic, Niigata 949-6600, Japan |
| 2019 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Tsurumi-ku 230-8501, Kanagawa, Japan;, (N.K.);, (A.S.);, (H.F.) Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2016 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan |
| 2015 | From the *Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa; and †Department of Ophthalmology, Tokyo Saiseikai Central Hospital; and ‡J&J Ocular Surface and Visual Optics Department, Keio University School of Medicine, Tokyo, Japan. |
| 2014 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2012 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa |
| 2011 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan. |
| 2010 | Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan. |
| 2009 | Department of Ophthalmology, Keio University, Tokyo, Japan. |
| 2008 | Department of Ophthalmology, International University of Welfare, Mita Hospital, Tokyo, Japan |
| 2007 | International University of Health and Welfare, Department of Ophthalmology, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan. |
| 2006 | From the *Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan; †Keio University School of Medicine, Tokyo, Japan; and ‡Hara Eye Clinic, Otawara, Tochigi Prefecture, Japan. Department of Ophthalmology, Keio University School of Medicine |
| 2005 | From the Department of Ophthalmology, Keio University, Tokyo, Japan; the Department of Ophthalmology, Tokyo Dental College, Sugano 5-11-13, Ichikawa, Chiba 272-8513, Japan |
| 2004 | From the Departments of *Ophthalmology and †Dermatology, Tokyo Dental College, Ichikawa, Chiba, Japan. Department of Ophthalmology, Keio University, Tokyo, Japan |
| 2003 | Department of Ophthalmology, Tokyo Dental College, Chiba, Japan |
| 2002 | Department of Ophthalmology, Tokyo Dental College, Sugano, Ichikawa, Japan. |
| 2001 | From the Departments of Ophthalmology (N.A-K., K.F., K.T., K.U., H.F.) and Dermatology (S.T.), Tokyo Dental College, Chiba, Japan. |
| 1998 | Department of Ophthalmology, Tokyo Dental College, Ichikawa, Chiba, Japan. |
| 1997 | Department of Ophthalmology, Tokyo Dental College, Chiba |
| 1996 | Department of Ophthalmology, Tokyo Dental College; Department of Ophthalmology, Keio University School of Medicine |
| 1995 | Chiba, Tokyo, and Akita, Japan Department of Ophthalmology Tokyo Dental College, Chiba |
| 1994 | Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan. |
Hiroshi Fujishima：統計に影響を与えます
レポートを実行します
| Concept | World rank |
|---|---|
| allergic corneal | #1 |
| fourgraded severity | #1 |
| conjunctivitis including | #1 |
| drop levocabastine | #1 |
| efficacy fml | #1 |
| akc treatment | #1 |
| allergens levocabastine | #1 |
| commercial eyewash solutions | #1 |
| 0001 allerwatch | #1 |
| tacrolimus ophthalmic | #1 |
| experience 01 | #1 |
| 3 months signs | #1 |
| tacrolimus tears | #1 |
| scores hyperemia | #1 |
| akc tear | #1 |
| adverse events scores | #1 |
| eyewash solutions | #1 |
| epithelium disorders | #1 |
| levocabastine artificial | #1 |
| fluorometholone 002 | #1 |
| diseases tear | #1 |
| initiation tacrolimus treatment | #1 |
| cox2 conjunctival | #1 |
| therapy levocabastine | #1 |
| stat6results | #1 |
| allergic enzyme | #1 |
| akc allergic | #1 |
| suppressing pge2 production | #1 |
| tacrolimus ophthalmic suspension | #1 |
| hyperemia pain | #1 |
| akc administration | #1 |
| drops elicited | #1 |
| eyebon | #1 |
| primary human conjunctival | #1 |
| fumarate dexamethasone | #1 |
| conjunctivitis conjunctival | #1 |
| allergenmediated conjunctivitis | #1 |
| 01 ophthalmic solution | #1 |
| eye itching | #1 |
| eyewash solution | #1 |
| capilia adeno eye | #1 |
| cd3 cd4bearing cells | #1 |
| allergic conjunctivitis drop | #1 |
| bf fml | #1 |
| tranilast eotaxin1 | #1 |
| vkc conclusions | #1 |
| severe binocular conjunctivitis | #1 |
| ocular allergic diseases | #1 |
| conjunctivitis seasonal | #1 |
| instillation bromfenac | #1 |
| cedrus conjunctivitis | #1 |
| compared fluorometholone | #1 |
| characterized conjunctival | #1 |
| conjunctivitis concomitantly | #1 |
| tacrolimus eye treatment | #1 |
| washing allergens | #1 |
| epithelial pge2 | #1 |
| akc vernal | #1 |
| commercial eyewash | #1 |
| improvement combinedtreatment | #1 |
| dscg fml | #1 |
| adult cedrus conjunctivitis | #1 |
| bromfenac sodium treatment | #1 |
| patients allergic conjunctivitis | #1 |
| keratoconjunctivitis vernal | #1 |
| radioimmunoassay il4 | #1 |
| allergic postoperative | #1 |
| artificial tears positive | #1 |
| solution allergic | #1 |
| action child conjunctivitis | #1 |
| instillation symptoms | #1 |
| eye allerwatch | #1 |
| solution ocular | #1 |
| eye surface years | #1 |
| akc compared | #1 |
| il4 causing | #1 |
| rsv conjunctival | #1 |
| binocular conjunctivitis | #1 |
| sodium bf | #1 |
| sodium allergic | #1 |
| sodium ophthalmic solution | #1 |
| talymus | #1 |
| clinical signs akc | #1 |
| severe conjunctivitis eyes | #1 |
| tranilast dexamethasone | #1 |
| conjunctival fibroblasts production | #1 |
| efficacy bromfenac sodium | #1 |
| suspension treating | #1 |
| production tranilast | #1 |
| tacrolimus ophthalmic solution | #1 |
| conclusions objective assessments | #1 |
| dha western blotting | #1 |
| allerwatch positivity rate | #1 |
| higher capilia | #1 |
| il4 tranilast | #1 |
| 12 patients akc | #1 |
| commercial washing solution | #1 |
| tears conjunctival fibroblasts | #1 |
| akc vkc | #1 |
| dscg bf | #1 |
| allergic tranilast | #1 |
| eotaxin1 production | #1 |
| antagonists child conjunctivitis | #1 |
| dscg 005 | #1 |
| keratoconjunctivitis background | #1 |
| include conjunctival | #1 |
| systemic control pain | #1 |
| ded anti | #1 |
| conjunctivitis aims | #1 |
| nsaids systemic control | #1 |
| vkc cases | #1 |
| tears allergic patients | #1 |
| selective chemotactic effects | #1 |
| itching levocabastine | #1 |
| pcr eotaxin1 | #1 |
| conjunctivitis helper | #1 |
| postoperative conjunctivitis | #1 |
| tacrolimus eye drop | #1 |
| levocabastine artificial tears | #1 |
| subjective ocular symptoms | #1 |
| conjunctivitis enrolled | #1 |
| diagnostic accuracy conjunctivitis | #1 |
| allerwatch higher | #1 |
| tranilast production | #1 |
| accuracy conjunctivitis | #1 |
| eye fml | #1 |
| samples allergic conjunctivitis | #1 |
| child conjunctivitis | #1 |
| production ketotifen fumarate | #1 |
| bak epithelium | #1 |
| keratocytes tnfα | #1 |
| allergic docosahexaenoic | #1 |
| akc methods | #1 |
| test capilia | #1 |
| bf concomitantly | #1 |
| hundredandseventy eyes | #1 |
| pge2 human conjunctival | #1 |
| bromfenac sodium bf | #1 |
| eyewash solutions bak | #1 |
| tears allergic | #1 |
| atopic keratoconjunctivitis akc | #1 |
| atopic keratoconjunctivitis | #1 |
| keratoconjunctivitis akc | #1 |
| scleritis tacrolimus | #1 |
| allerwatch tests | #1 |
| il4 tear | #1 |
| rate allerwatch | #1 |
| adenovirus capilia | #1 |
| corneal epithelium disorders | #1 |
| treatment vernal keratoconjunctivitis | #1 |
| dscg symptoms | #1 |
| eyebon eye | #1 |
| akc patients | #1 |
| conjunctivitis treated | #1 |
| satisfaction suspensions | #1 |
| exacerbation vkc | #1 |
| bromfenac sodium | #1 |
| eyewash | #1 |
| cases severe conjunctivitis | #1 |
| signs palpebral | #1 |
| higher akc | #1 |
| tnfalpha tranilast dexamethasone | #1 |
| conjunctivitis japanese | #1 |
| eyewash solution bak | #1 |
| concomitant bf | #1 |
| itchy sensation | #1 |
| fml administered | #1 |
| immunocytochemical study rtpcr | #1 |
| rapid ophthalmic | #1 |
| bak epithelium disorders | #1 |
| eye wash | #1 |
| fml dscg | #1 |
| incubated interleukin | #1 |
| vkc april | #1 |
| patients capilia | #1 |
| ige allerwatch | #1 |
| allerwatch diagnostic accuracy | #1 |
| keratoconjunctivitis male | #1 |
| conjunctival cedar | #1 |
| vkc akc | #1 |
| severity objective signs | #1 |
| cytokinestimulation pharmacologic intervention | #1 |
| 01 tacrolimus eye | #1 |
| bromobenzenes conjunctivitis | #1 |
| positivity rate allerwatch | #1 |
| objective findings conclusions | #1 |
| patients atopic keratoconjunctivitis | #1 |
| eotaxin conjunctival fibroblasts | #1 |
| capilia adeno | #1 |
| iop akc | #1 |
| selected fml | #1 |
| akc | #1 |
| severe akc | #1 |
| adeno eye | #1 |
| allergic conjunctivitis | #1 |
| patients akc | #1 |
| prostaglandin tears | #1 |
| tacrolimus eye drops | #1 |
| fml 002 | #1 |
| fml patients | #1 |
| 10 objective signs | #1 |
| conjunctival fibroblasts | #1 |
| tacrolimus eye | #1 |
| release inhibitor purpose | #1 |
| patients severe conjunctivitis | #1 |
| production conjunctival fibroblasts | #1 |
| dha il4 | #1 |
| allergic conjunctivitis efficacy | #1 |
| inhibition eotaxin1 | #1 |
| initiating tacrolimus | #1 |
| conjunctivitis scleritis episcleritis | #1 |
| ketotifen fumarate dexamethasone | #1 |
| dryness scores | #2 |
| papillary formation | #2 |
| diabetic patients ono2235 | #2 |
| akc young adult | #2 |
| effects topical tacrolimus | #2 |
| edema corneal damage | #2 |
| ophthalmic nsaid | #2 |
| metaregression analysis glaucoma | #2 |
| atopic diagnostic techniques | #2 |
| period rhodanine | #2 |
| akc patients correlation | #2 |
| baseline papillae | #2 |
| muc16 immunohistochemistry | #2 |
| cobblestonelike papillae | #2 |
| conjunctivitis condition | #2 |
| representative subjective | #2 |
| papillae preventing | #2 |
| extents corneal | #2 |
| correlation neutrophils | #2 |
| ensured proving | #2 |
| allergy accompanied | #2 |
| conjunctival injection reduction | #2 |
| lesions allergic | #2 |
| corneal recurrences | #2 |
| allergic diagnosis | #2 |
| noninferiority olopatadine | #2 |
| month eyewash | #2 |
| disease antiallergic | #2 |
| treatment ecp concentrations | #2 |
| excision cobblestone | #2 |
| conjunctiva bulbar | #2 |
| solutions japan | #2 |
| cutometer sem575 | #2 |
| tacrolimus iop | #2 |
| proliferative called | #2 |
| eyewash 005 | #2 |
| sem575 clinical | #2 |
| epitheliopathy patients | #2 |
| eyelid atopic | #2 |
| bromfenac sodium bromfenac | #2 |
| severity eyelid | #2 |
| drops hyperemia | #2 |
| conjunctiva papillary | #2 |
| brush cytology patients | #2 |
| patients corneal ulcers | #2 |
| skin elasticity patients | #2 |
| elasticity severity | #2 |
| conjunctival findings severity | #2 |
| brush cytology samples | #2 |
| scores papillary | #2 |
| methods thirtysix patients | #2 |
| swelling folliculosis | #2 |
| drop steroid | #2 |
| defined conjunctival | #2 |
| tear ige correlation | #2 |
| concomitantly abovementioned | #2 |
| regrowth 7 eyes | #2 |
| sodium ophthalmic | #2 |
| 001 brush | #2 |
| epitheliopathy refractory | #2 |
| simple resection regrowth | #2 |
| diathesis subjective | #2 |
| olopatadine visit | #2 |
| limbal swelling | #2 |
| tacrolimus shield | #2 |
| tacrolimus detection limit | #2 |
| dermatitis remission | #2 |
| akc adult | #2 |
| severity corneal complications | #2 |
| cac test | #2 |
| signs blood concentration | #2 |
| pollutants prevalence | #2 |
| epitheliopathy score | #2 |
| based papillae | #2 |
| treatment atopic blepharitis | #2 |
| treatment total signs | #2 |
| akc aureus | #2 |
| sem575 quantitatively | #2 |
| 1 month tacrolimus | #2 |
| iop topical steroids | #2 |
| immunoregulatory effects study | #2 |
| lacrimation objective | #2 |
| sem575 | #2 |
| eosinophils corneal damage | #2 |
| vkc japan | #2 |
| objective signs baseline | #2 |
| evaluate superiority | #2 |
| placebo noninferiority | #2 |
| allergic endophthalmitis | #2 |
| bromfenac ophthalmic solution | #2 |
| administered elf bovine | #2 |
| akc sac patients | #2 |
| including akc | #2 |
| tacrolimus detection | #2 |
| 18 akc | #2 |
| lid skin | #2 |
| recurrence corneal lesions | #2 |
| papillae mucous discharge | #2 |
| production specular | #2 |
| papillary excision | #2 |
| drops refractory | #2 |
| premedication combined | #2 |
| bromfenac effective | #2 |
| lessen steroid | #2 |
| diagnosis ensured | #2 |
| shield ulcers patients | #2 |
| drops conjunctival | #2 |
| japan topical | #2 |
| atopic blepharitis | #2 |
| japan topical tacrolimus | #2 |
| japan akc | #2 |
| tacrolimus topical | #2 |
| prevalence akc | #2 |
| epitheliopathy steroids | #2 |
| mmc 7 eyes | #2 |
| test papillae | #2 |
| ecp levels akc | #2 |
| ceramide gel application | #2 |
| bovine entericcoated lactoferrin | #2 |
| 2helper cell | #2 |
| adjuvant fluorometholone | #2 |
| selected bf | #2 |
| treatment tear | #2 |
| conjunctivitis epitheliopathy | #2 |
| conjunctivitis representative | #2 |
| plaques 791 | #2 |
| score adjustments | #2 |
| rhodanine rose | #2 |
| oral ari | #2 |
| nonpreserved eyewash solution | #2 |
| aureussecreted enterotoxins | #2 |
| papillae akc | #2 |
| topical antiallergic agents | #2 |
| eyes 824 | #2 |
| patients shield ulcers | #2 |
| oral ari ono2235 | #2 |
| tacrolimus 12 weeks | #2 |
| neutrophils corneal damage | #2 |
| epitheliopathy shield | #2 |
| seasonal allergic conjunctivitis | #2 |
| refractory allergic | #2 |
| normal blinking patients | #2 |
| akc 1 | #2 |
| effects tacrolimus | #2 |
| akc 6 | #2 |
| allergic conjunctivitis ige | #2 |
| adjuvant fluorometholone 95 | #2 |
| conventional antiallergic drugs | #2 |
| epinastine ophthalmic solution | #2 |
| bovine placebo | #2 |
| fluorescein conjunctival injection | #2 |
| adjuvant betamethasone | #2 |
| ocular surface mucin | #2 |
| conjunctivitis adolescent | #2 |
| post cataract surgery | #2 |
| excision cobblestonelike papillae | #2 |
| corneal complications height | #2 |
| tacrolimus published data | #2 |
| ecp severity markers | #2 |
| corneal epithelial signs | #2 |
| ulcer complain | #2 |
| suspension lactoferrin | #2 |
| patients severe akc | #2 |
| mucous discharge severity | #2 |
| height papillae | #2 |
| signs decreased | #2 |
| conjunctivitis purpose | #2 |
| asthma heart diseases | #2 |
| aided papillary | #2 |
| patients tacrolimus eye | #2 |
| akc adolescent | #2 |
| csa akc | #2 |
| olopatadine cedar | #2 |
| corneal lesions regrowth | #2 |
| mmc aided | #2 |
| conjunctivitis 10 | #2 |
| severity corneal lesions | #2 |
| corneal damage height | #2 |
| cytodiagnosis dermatitis | #2 |
| female humans akc | #2 |
| akc 10 | #2 |
| allergic conjunctivitis levocabastine | #2 |
| deqs tear | #2 |
| unpaired ttest talymus | #2 |
| tarsal brush | #2 |
| talymus akc | #2 |
| conjunctival injection edema | #2 |
| akc 10 eyes | #2 |
| ari ocular | #2 |
| corneal epitheliopathy | #2 |
| lactoferrin 01 | #2 |
| solution epinastine | #2 |
| corneal lesions | #2 |
| akc treated | #2 |
| control subjects eyes | #2 |
| epinastine 15 minutes | #2 |
| tacrolimus 1 month | #2 |
| conclusions bromfenac | #2 |
| blepharitis ceramides | #2 |
| keratoconjunctivitis age | #2 |
| improvement corneal fluorescein | #2 |
| conjunctivitis proliferative | #2 |
| decrease corneal temperature | #2 |
| elasticity eyelid | #2 |
| study designopen cohort | #2 |
| eyelid skin elasticity | #2 |
| corneal damage patients | #2 |
| tear film layer | #2 |
| corneal ulcers patients | #2 |
| sac healthy | #2 |
| akc allergic diagnosis | #2 |
| simple papillary resection | #2 |
| superiority epinastine | #2 |
| formation palpebral | #2 |
| eyes betamethasone | #2 |
| mucin analyzed | #2 |
| edema height | #2 |
| air pollutants prevalence | #2 |
| improvement vital staining | #2 |
| allergic conjunctivitis akc | #2 |
| administration specular | #2 |
| adjustments epitheliopathy score | #2 |
| 95 adjuvant betamethasone | #2 |
| correlation eosinophils | #2 |
| vkc atopic keratoconjunctivitis | #2 |
| tacrolimus tonometry | #2 |
| epinastine superiority | #2 |
| score topical | #2 |
| regrowth papillae | #2 |
| conjunctival corneal cells | #2 |
| akc levels | #2 |
| environmental studies prevalence | #2 |
| treatment shield ulcer | #2 |
| elevation tacrolimus | #2 |
| tacrolimus lessen | #2 |
| epitheliopathy corneal | #2 |
| hyperemia lacrimation | #2 |
| papillae limbus | #2 |
| total signs symptoms | #2 |
| ketotifen dexamethasone | #2 |
| total clinical signs | #2 |
| betamethasone glaucoma | #2 |
| corneal findings | #2 |
| corneal temperature patients | #2 |
| inflammatory child child | #2 |
| cedrus conjunctiva | #2 |
| cornea grading | #2 |
| 062 tear | #2 |
| papillae severe | #2 |
| accompanied subjective | #2 |
| vkc 5 | #2 |
| detected akc | #2 |
| treated bromfenac | #2 |
| formation akc | #2 |
| papilla accompanied | #2 |
| administered elf | #2 |
| oral ari administration | #2 |
| correlation fluorescein | #2 |
| severe allergic conjunctivitis | #2 |
| benzophenones bromobenzenes | #2 |
| eyelid elasticity | #2 |
| neutrophils brush | #2 |
| lower conjunctival sacs | #2 |
| sodium bromfenac | #2 |
| conjunctiva conjunctivitis allergic | #2 |
| complain foreign | #2 |
| eyelid atopic dermatitis | #2 |
| drop concomitantly | #2 |
| steroid metaregression | #2 |
| resolution thermography | #2 |
| efficacy severe akc | #2 |
| pge2 tears | #2 |
| factor vkc | #2 |
| largescale study protocol | #2 |
| oral aldose | #2 |
| conjunctivitis retrospective | #2 |
| steroids epitheliopathy | #2 |
| giant papillary formation | #2 |
| corneal epitheliopathy score | #2 |
| folliculosis papillae | #2 |
| scores tacrolimus | #2 |
| adjustments epitheliopathy | #2 |
| severity corneal damage | #2 |
| conjunctiva atopic | #2 |
| patients shield | #2 |
| tears akc | #2 |
| topical tacrolimus combination | #2 |
| keratoconjunctivitis corneal | #2 |
| serum allergic parameters | #2 |
| nonwash | #2 |
| suspension talymus | #2 |
| recurrence corneal complications | #2 |
| olopatadine ocular | #2 |
| reported eotaxin | #2 |
| endpoint itching scale | #2 |
| giant papillae formation | #2 |
| tears thiazolidines | #2 |
| reaction conjunctiva | #3 |
| traumatic swelling | #3 |
| production conjunctival | #3 |
| allergic patients conjunctivitis | #3 |
| local tear deficiency | #3 |
| rtpcr par2 | #3 |
| treatment atopic keratoconjunctivitis | #3 |
| corneal complications1 | #3 |
| patching patient | #3 |
| tear periostin comorbidities | #3 |
| samples correlate | #3 |
| tissue remodeling exacerbation | #3 |
| tear periostin | #3 |
| healing dramatic healing | #3 |
| periostin akc | #3 |
| lacrimal punctal occlusion | #3 |
| interleukin4 histamine | #3 |
| vkc relevant factor | #3 |
| icecold eye mask | #3 |
| vkc fibronectin | #3 |
| histamine superficial cells | #3 |
| postsurgical conjunctivitis | #3 |
| papillary resection | #3 |
| 5ac brush | #3 |
| diseases acds | #3 |
| macroerosions | #3 |
| dfna eye | #3 |
| eyes allergic | #3 |
| aged elisa | #3 |
| sde controls | #3 |
| operation eye | #3 |
| uncontrollable glaucoma | #3 |
| histamine cedar pollen | #3 |
| uncontrollable glaucoma trabeculectomy | #3 |
| akc periostin | #3 |
| tryptase conjunctiva | #3 |
| higher muc1 eyes | #3 |
| dscg administration | #3 |
| muc1 brush cytology | #3 |
| giant papilla | #3 |
| hydrochloride 01 | #3 |
| superior keratoconjunctiva | #3 |
| inflammation mmc | #3 |
| eyes control subjects | #3 |
| dibenzoxepins female | #3 |
| july pm25 | #3 |
| papillary regrowth | #3 |
| cultured tryptase | #3 |
| insensible administration insensible | #3 |
| hyperemia allergic | #3 |
| mmc excision | #3 |
| ulcer akc | #3 |
| prospectively diclofenac | #3 |
| techniques tears | #3 |
| eye cooling | #3 |
| tear periostin biomarker | #3 |
| cases vkc | #3 |
| cooling cataract | #3 |
| differences dfna | #3 |
| corneal akc | #3 |
| par2 cultured | #3 |
| vkc eyes | #3 |
| conjunctival fibroblasts rtpcr | #3 |
| sensitivity tear | #3 |
| vkc exacerbation | #3 |
| 5 eyes akc | #3 |
| proving type | #3 |
| conjunctivitis lymphocytes | #3 |
| nonpreserved artificial tears | #3 |
| corneal epithelial structure | #3 |
| allergic postsurgical | #3 |
| elisa histamine | #3 |
| akc dyes humans | #3 |
| conjunctival corneal | #3 |
| 005 ophthalmic solution | #3 |
| permeability postoperatively | #3 |
| autumnal pollen | #3 |
| outpatient attendance july | #3 |
| conjunctivitis negative | #3 |
| erosions refractory | #3 |
| membrane uncontrollable | #3 |
| insufficient tear | #3 |
| cornea atopic | #3 |
| 12 akc patients | #3 |
| allergic cornea | #3 |
| keratoconjunctivitis vkc | #3 |
| 1 month initiation | #3 |
| cell metry | #3 |
| vkc long | #3 |
| vkc 5 eyes | #3 |
| topical cyclosporine 01 | #3 |
| cytology impression | #3 |
| cell flare count | #3 |
| pollen august | #3 |
| adedry eye | #3 |
| formation vernal | #3 |
| histamine cedar | #3 |
| laser flarecellmetry | #3 |
| tmh measurement | #3 |
| insufficient tear supply | #3 |
| mmcaided papillary resection | #3 |
| diclofenac epithelium | #3 |
| il1beta th2 | #3 |
| 12 akc | #3 |
| conjunctiva allergic | #3 |
| commercial washing | #3 |
| protein conjunctival fibroblasts | #3 |
| 111 177 | #3 |
| aged biological dressings | #3 |
| 21 akc | #3 |
| epinastine placebo | #3 |
| eyes akc | #3 |
| central corneal temperature | #3 |
| histamine specimens | #3 |
| normal controls collagens | #3 |
| pilocarpine visante | #3 |
| treatment oral pilocarpine | #3 |
| mmc authors | #3 |
| patching case | #3 |
| conjunctivitis allergic | #3 |
| temperature evaluate | #3 |
| cholinergic treatment response | #3 |
| vivo corneal akc | #3 |
| superior limbic portion | #3 |
| akc serum periostin | #3 |
| study cutometer | #3 |
| nbs subbasal | #3 |
| nbs normal eyes | #3 |
| 21 akc patients | #3 |
| flare metry | #3 |
| aureus akc patients | #3 |
| evaluate tear | #3 |
| injections keratoconjunctivitis | #3 |
| conjunctival fibroblasts tryptase | #3 |
| conjunctivitis benzamidines | #3 |
| fibronectin normal controls | #3 |
| tears treatment | #3 |
| treatment strip meniscometry | #3 |
| vkc levels | #3 |
| 01 ophthalmic | #3 |
| pm25 outpatient attendance | #3 |
| outpatient visits august | #3 |
| cases vernal | #3 |
| antiallergic eye drop | #3 |
| dfna control | #3 |
| underwent staining | #3 |
| 01 bromfenac | #3 |
| patients tmh measurements | #3 |
| sdedry eye | #3 |
| treatment skin elasticity | #3 |
| par2 benzamidines blotting | #3 |
| fibronectin vkc | #3 |
| 005 mmc | #3 |
| interleukin4 tacrolimus | #3 |
| akc rose bengal | #3 |
| diclofenac eye drops | #3 |
| akc confocal | #3 |
| titers ade | #3 |
| existence par2 | #3 |
| decline corneal | #3 |
| akc comorbidities | #3 |
| induced inflammation lenses | #3 |
| eosinophils corneal | #3 |
| akc confocal microscopy | #3 |
| antibody titers ade | #3 |
| lamp device | #3 |
| 13 eyes 69 | #3 |
| allergic conjunctivitis aged | #3 |
| severe allergy patients | #3 |
| conjunctiva conjunctivitis | #3 |
| epithelium adverse | #3 |
| tear il13 | #3 |
| phenomena tacrolimus | #3 |
| ssdry | #3 |
| 005 collagens | #3 |
| glaucoma amniotic | #3 |
| antieaigg | #3 |
| ophthalmic solution placebo | #3 |
| ari corneal | #3 |
| tear periostin patients | #3 |
| vkc differences | #3 |
| metry dfna | #3 |
| tears adolescent | #3 |
| allergic corneal diseases | #3 |
| akc tear periostin | #3 |
| technique 2 eyes | #3 |
| surgery dfna | #3 |
| portable recordable | #3 |
| weekly average values | #3 |
| fibers lnfs | #3 |
| 22 eyes 100 | #3 |
| drops treat | #3 |
| periostin comorbidities | #3 |
| conjunctivitis pm25 | #3 |
| techniques conjunctivitis | #3 |
| oct graticule | #3 |
| dfna diclofenac epithelium | #3 |
| histamine conjunctival cells | #3 |
| severe allergic patients | #3 |
| increased comfort | #3 |
| pollen postoperative | #3 |
| outpatient visits july | #3 |
| vkc papillae | #3 |
| benzamidine par2 | #3 |
| measurements schirmer | #3 |
| strip meniscometry testing | #3 |
| 5ac mrna | #3 |
| ulcer persistent | #3 |
| pretreatment docosahexaenoic acid | #3 |
| akc higher | #3 |
| ecp severity | #3 |
| treatment vernal | #3 |
| thermography evaluate | #3 |
| scale tmh | #3 |
| lnfs nbs | #3 |
| healing allergic | #3 |
| technique uncontrollable | #3 |
| lower muc5ac | #3 |
| improvement squamous metaplasia | #3 |
| akc persistent | #3 |
| existence par2 mrna | #3 |
| ophthalmic solution nsaid | #3 |
| allergic corneal ulcer | #3 |
| ulcers plaques | #3 |
| drop selected | #3 |
| sligkv examined | #3 |
| akc eyes | #3 |
| rose bengal akc | #3 |
| dramatic healing | #3 |
| eyes vkc | #3 |
| scored global | #3 |
| eye washing | #3 |
| vkc cell | #3 |
| vkc sac | #3 |
| healed amniotic | #3 |
| periostin topical | #3 |
| cells brush cytology | #3 |
| prophylaxis conjunctival | #3 |
| akc biomarkers | #3 |
| superficial cells conjunctiva | #3 |
| dfna eye dfna | #3 |
| akc alterations | #3 |
| corneal ulceration role | #3 |
| il1beta th2 cytokines | #3 |
| diabetic corneal disease | #3 |
| fluorescein glycyrrhizic | #3 |
| ebv ade | #3 |
| ocular surface diabetes | #3 |
| allerwatch | #3 |
| papillae morphometric | #3 |
| dry eye eye | #3 |
| 3 sjögrens syndrome | #3 |
| efficacy bromfenac | #3 |
| conjunctival disease | #3 |
| solutions prospective | #3 |
| keratoconjunctivitis leupeptins | #3 |
| formation vkc | #3 |
| signs remission | #3 |
| pm25 allergic | #3 |
| infrared radiation thermography | #3 |
| patients pilocarpine tablets | #3 |
| ulcers eyes | #3 |
| association outpatient attendance | #3 |
| alterations tear | #3 |
| fluorescein scale | #3 |
| immunosuppressive eye | #3 |
| akc atopic dermatitis | #3 |
| underwent periodic | #3 |
| nuclei vkc | #3 |
| oct tmh | #3 |
| relevant factor exacerbation | #3 |
| child conjunctiva | #3 |
| papillae upper | #3 |
| akc higher muc1 | #3 |
| laser cellflaremetry | #3 |
| tryptase increases | #3 |
| 020 013 | #4 |
| vkc messenger reverse | #4 |
| conjunctivitis vkc | #4 |
| controls brush cytology | #4 |
| allergic patients elisa | #4 |
| specimens underwent | #4 |
| steroids iop | #4 |
| conjunctival proliferative | #4 |
| studied corneal | #4 |
| hydrochloride ophthalmic | #4 |
| bromfenac ophthalmic | #4 |
| patients topical cyclosporine | #4 |
| male ophthalmic | #4 |
| moisture checker | #4 |
| muc5ac alterations | #4 |
| papillae normal | #4 |
| blinding purpose | #4 |
| underwent corneal | #4 |
| erosion shield | #4 |
| goblet cell muc5ac | #4 |
| epithelial pge2 production | #4 |
| rose bengal scores | #4 |
| chemotaxis conjunctiva | #4 |
| steroids fluorometholone | #4 |
| severe vkc patients | #4 |
| thermometer 20 | #4 |
| subjects muc5ac | #4 |
| oedema papillary | #4 |
| eyes video | #4 |
| conjunctiva allergic conjunctivitis | #4 |
| ari ono2235 | #4 |
| eosinophils receptor crth2 | #4 |
| staining muc16 | #4 |
| ded 1 | #4 |
| membrane patching | #4 |
| epithelial muc | #4 |
| levocabastine ophthalmic | #4 |
| thermography anterior | #4 |
| controls interferometry grade | #4 |
| hypersensitivity mucin | #4 |
| chemokine genes fibroblasts | #4 |
| tnfalpha30ng | #4 |
| level conjunctiva | #4 |
| treatment vmr | #4 |
| keratoconjunctivitis purpose | #4 |
| vkc 4 | #4 |
| akc healthy | #4 |
| lower tear clearance | #4 |
| persistent 6 | #4 |
| controls interferometry | #4 |
| sio2 20 | #4 |
| special brush | #4 |
| mucins 1 | #4 |
| ophthalmologists evaluated | #4 |
| pgd2 normal volunteers | #4 |
| crth2 akc | #4 |
| simple resection | #4 |
| interferometry lipids | #4 |
| surface muc5ac | #4 |
| trantas | #4 |
| weeks vital | #4 |
| giemsas staining | #4 |
| corneal safety | #4 |
| muc16 muc5ac alterations | #4 |
| healthy individuals rtpcr | #4 |
| vkc conjunctiva conjunctivitis | #4 |
| tear function patients | #4 |
| solutions piperidines | #4 |
| exponential equation inclination | #4 |
| include ocular | #4 |
| 2010 allergic | #4 |
| adolescent betamethasone | #4 |
| epithelial disease eyes | #4 |
| papillae giant | #4 |
| metaplasia reduction | #4 |
| cultured conjunctival | #4 |
| tears 10 patients | #4 |
| ige conjunctival | #4 |
| eyes ulcers | #4 |
| acds conventional | #4 |
| interferometry controls | #4 |
| thinoptx | #4 |
| tomography tear | #4 |
| tears pathogenesis | #4 |
| 3004 respondents | #4 |
| cytology goblet | #4 |
| samples allergic | #4 |
| implantation thinoptx | #4 |
| ulcers atopic | #4 |
| excision papillary | #4 |
| eyes sac | #4 |
| allergic conjunctivitis rsv | #4 |
| untreated asian dust | #4 |
| ulcers mucin | #4 |
| genes conjunctival | #4 |
| ulcers control subjects | #4 |
| acuity akc | #4 |
| metaregression analysis effects | #4 |
| corneal temperature eye | #4 |
| limbal grafts | #4 |
| eosinophil toxic activity | #4 |
| greater concentrations tears | #4 |
| cornea grading scale | #4 |
| epinastine hydrochloride | #4 |
| insignificant epithelial disease | #4 |
| proteinchip array elisa | #4 |
| allergic rhinoconjunctivitis allergic | #4 |
| corneal ulcers eyes | #4 |
| asian dust extract | #4 |
| formation conjunctivitis | #4 |
| portable slit | #4 |
| 34 15 seconds | #4 |
| sac control eyes | #4 |
| fungi epidemiologic studies | #4 |
| topical oral steroids | #4 |
| fva treatment | #4 |
| assay pgd2 | #4 |
| tears patients | #4 |
| akc healthy individuals | #4 |
| sterilized asian dust | #4 |
| photophobia diagnosis | #4 |
| lower tear function | #4 |
| atopic ocular allergies | #4 |
| compared vkc | #4 |
| muc5ac brush cytology | #4 |
| dscg day | #4 |
| corneal temperature blink | #4 |
| bromfenac eye drops | #4 |
| performed tears | #4 |
| highrisk glaucoma patients | #4 |
| akc crth2 expression | #4 |
| sterilized asian | #4 |
| immunologic receptors akc | #4 |
| samples immunocytochemical | #4 |
| mucin mucins tears | #4 |
| allergic conjunctival disease | #4 |
| infected conjunctival | #4 |
| interferometry 2 | #4 |
| tablets tears | #4 |
| grade dry eye | #4 |
| vkc male receptors | #4 |
| 33 chemokines | #4 |
| stimulation chemokine expression | #4 |
| thinoptx intraocular | #4 |
| staining ocular | #4 |
| cases sufficient examination | #4 |
| 2 4 alterations | #4 |
| eyes akc patients | #4 |
| 10 seconds temperature | #4 |
| corneal ulcers muc5ac | #4 |
| rsv conjunctiva | #4 |
| akcaffected patients | #4 |
| eye sjögrens syndrome | #4 |
| muc1 2 | #4 |
| corneal sensitivity measurement | #4 |
| sensation tears | #4 |
| primary sources chemokines | #4 |
| alterations atopic | #4 |
| vmr 3 months | #4 |
| bengal sensation | #4 |
| ocular surface epithelial | #4 |
| akc immunologic receptors | #4 |
| il4 tears | #4 |
| patients severe vkc | #4 |
| placebo ophthalmic | #4 |
| microscope evaluating | #4 |
| conjunctival papillary | #4 |
| allergies blinding | #4 |
| sensitization asian dust | #4 |
| allergic cytological | #4 |
| recordable slit | #4 |
| greater 3 grade | #4 |
| epithelial cells rsv | #4 |
| individuals pgd2 | #4 |
| corneal sensitivity measurements | #4 |
| eotaxin1 rantes | #4 |
| diameter allergen | #4 |
| deqs scores | #4 |
| conjunctiva differences | #4 |
| ophthalmologists eye drops | #4 |
| akc pgd2dependent migration | #4 |
| eyes corneal ulcers | #4 |
| patient eyes fluorescein | #4 |
| interleukin2 tears | #4 |
| conjunctivitis methods | #4 |
| acds ophthalmologists | #4 |
| staining muc | #4 |
| 18 akc patients | #4 |
| allergic fibroblasts | #4 |
| allergic conjunctival | #4 |
| eye operation | #4 |
| july pollen | #4 |
| crth2 peripheral | #4 |
| tacrolimus conclusions | #4 |
| rsv conjunctival epithelium | #4 |
| surface conjunctival | #4 |
| muc16 goblet | #4 |
| temperature corneal | #4 |
| allergic conjunctivitis prostaglandin | #4 |
| eyes insignificant | #4 |
| atopic keratoconjunctivitis purpose | #4 |
| mucins tears mucin | #4 |
| tear temperature | #4 |
| aged rose | #4 |
| samples histocytological | #4 |
| 0001 brush | #4 |
| atopic vernal | #4 |
| lesions regrowth | #4 |
| wilcoxon signed test | #4 |
| cells lnfs | #4 |
| muc5ac mrna expression | #4 |
| severe ocular allergies | #4 |
| rsv allergic reaction | #4 |
| atopic ocular | #4 |
| akc sac | #4 |
| epithelial disease patients | #4 |
| eye wash solution | #4 |
| tear function test | #4 |
| fibroblasts primary sources | #4 |
| tryptase dose | #4 |
| sac grade | #4 |
| p0001 brush | #4 |
| defensins conjunctivitis | #4 |
| ocular allergic disease | #4 |
| folliculosis | #4 |
| par2 mrna protein | #4 |
| conjunctiva density | #4 |
| p0001 impression | #4 |
| treatment vmr values | #4 |
| rsv conjunctiva conjunctivitis | #4 |
| cytometry mild | #4 |
| atopic dermatitis remission | #4 |
| insignificant epithelial | #4 |
| allergic conjunctival diseases | #4 |
| scores conjunctival | #4 |
| allergic epidemiologic studies | #4 |
| noninfectious necrotizing | #4 |
| implantation rollable | #4 |
| eyes thinoptx | #4 |
| conjunctivitis ige | #4 |
| interferometry grade | #4 |
| thinoptx lens | #4 |
| histamine h1 antagonist | #4 |
| defensins greater | #4 |
| vkc normal controls | #4 |
| inflammation akc | #4 |
| eyes epithelial disease | #4 |
| rejection limbal | #4 |
| akc rtpcr | #4 |
| muc5ac brush | #4 |
| months papillary | #4 |
| pcr epithelial | #4 |
| completely severe | #4 |
| 061 028 degree | #4 |
| conjunctivitis levels | #4 |
| correlation outpatient | #4 |
| keratoconjunctivitis lacrimal | #4 |
| pgd2dependent migration eosinophils | #4 |
| cell muc5ac | #4 |
| akc crth2 | #4 |
| topical 01 tacrolimus | #4 |
| dust wheal | #4 |
| akc chemotaxis | #4 |
| disease akc | #4 |
| pgd2dependent migration | #4 |
| drop artificial tears | #4 |
| clinical conjunctival | #4 |
| epithelial muc16 | #4 |
| patients epithelial disease | #4 |
| thinoptx acrysof | #4 |
| 4 chemokines stimulation | #4 |
| diseases portable | #4 |
| patient atopic keratoconjunctivitis | #4 |
| levocabastine h1 | #4 |
| conventional portable | #4 |
| pathogenesis noninfectious | #4 |
| cytometry mild cases | #4 |
| eosinophils activated fibroblasts | #5 |
| worse akc | #5 |
| ocular surface disorder | #5 |
| punctal occlusion oct | #5 |
| 5 females akc | #5 |
| diclofenac eye | #5 |
| anterior scleritis patients | #5 |
| supernatants conjunctival | #5 |
| disposable eyelid | #5 |
| human conjunctival fibroblasts | #5 |
| vkc iop | #5 |
| adolescent conjunctivitis | #5 |
| 20 sio2 | #5 |
| disposable eyelidwarming device | #5 |
| bromobenzenes cornea | #5 |
| staining muc5ac | #5 |
| eye warmer | #5 |
| staining administration | #5 |
| array chemotaxis | #5 |
| ulcers controls | #5 |
| akc normal subjects | #5 |
| signs akc | #5 |
| impression cytology samples | #5 |
| controls ebv | #5 |
| conjunctival inflammatory status | #5 |
| anterior fluorometry | #5 |
| visits july | #5 |
| allergic drug therapy | #5 |
| accompanied varying | #5 |
| solution olopatadine | #5 |
| vcam1 fibroblasts | #5 |
| scores expressibility | #5 |
| ulcer dermatitis | #5 |
| warmer improved | #5 |
| hel akc | #5 |
| dryeye symptoms | #5 |
| 0001 strip | #5 |
| cells vkc | #5 |
| mcfg eye | #5 |
| asthenopia dry | #5 |
| 20 akc patients | #5 |
| ocular allergic | #5 |
| postsurgical inflammation | #5 |
| topical cyclosporine therapy | #5 |
| inflammatory cells hel | #5 |
| akc ecp | #5 |
| lower atopic | #5 |
| ophthalmic suspension | #5 |
| bengal suture | #5 |
| oct lower | #5 |
| equipment dry | #5 |
| ihc conjunctival inflammation | #5 |
| severe stevensjohnson syndrome | #5 |
| treatment shield | #5 |
| situ nickend regulation | #5 |
| 17 mgd patients | #5 |
| schiff immunohistochemical | #5 |
| younger age effects | #5 |
| stainings tear | #5 |
| akc patients study | #5 |
| upper palpebral | #5 |
| damage impression | #5 |
| keratoconjunctivitis giant | #5 |
| 329±57 years | #5 |
| month tear | #5 |
| measurements strip | #5 |
| thiazolidines administration | #5 |
| cornea cytodiagnosis | #5 |
| mitomycin excision | #5 |
| lipid oxidation hel | #5 |
| allergic cyclosporine | #5 |
| regulation allergic cornea | #5 |
| ophthalmic test | #5 |
| 15 minutes dose | #5 |
| disease conjunctivitis | #5 |
| inflammation mitomycin | #5 |
| cases tests | #5 |
| intraoperative mitomycin excision | #5 |
| trantas dots | #5 |
| 01 mcfg | #5 |
| conjunctiva dermatitis | #5 |
| allergic conjunctivitis patients | #5 |
| severe conjunctivitis | #5 |
| status confocal | #5 |
| corneal involvement | #5 |
| 376±56 years | #5 |
| adhered corneal | #5 |
| stimulated conjunctival | #5 |
| conjunctival confocal microscopy | #5 |
| vkc atopic | #5 |
| visits august | #5 |
| females akc | #5 |
| pgd2 normal | #5 |
| conjunctiva mmc | #5 |
| age 9 ± | #5 |
| tnfα costimulation | #5 |
| alpha allergic | #5 |
| allergic keratopathy | #5 |
| eye circulating | #5 |
| meniscus punctal | #5 |
| solutions pollen | #5 |
| wilcoxonmatched pair test | #5 |
| cornea explain | #5 |
| damaged eosinophil | #5 |
| 3 cases followup | #5 |
| fibroblasts fibroblast damage | #5 |
| accompanying allergic | #5 |
| layer mgd | #5 |
| pm25 outpatient | #5 |
| eosinophils immunologic receptors | #5 |
| akc hel | #5 |
| prostaglandin chemotaxis | #5 |
| months amniotic | #5 |
| keratoconjunctivitis objective | #5 |
| eosinophil adherence fibroblasts | #5 |
| scans akc | #5 |
| il4 histamine | #5 |
| impression brush | #5 |
| study epinastine | #5 |
| diseases required | #5 |
| conjunctival lipid | #5 |
| endophthalmitis eosinophils | #5 |
| schirmer1 test groups | #5 |
| antifungal mcfg | #5 |
| corneal fibroblasts icam1 | #5 |
| case corneal ulcer | #5 |
| hne ihc | #5 |
| controls inflammatory cells | #5 |
| allergic conjunctiva conjunctivitis | #5 |
| 7 conjunctival | #5 |
| tears received | #5 |
| injection conjunctival | #5 |
| severity akc | #5 |
| conventional steroid treatment | #5 |
| cytokinestimulation | #5 |
| conjunctival allergen | #5 |
| treatment dryeye symptoms | #5 |
| 310±165 years | #5 |
| akc laser | #5 |
| akc acinar | #5 |
| local tear | #5 |
| warmer applied | #5 |
| 005 schirmer1 | #5 |
| treatment tacrolimus ointment | #5 |
| pretreatment dha | #5 |
| eye warmer treatment | #5 |
| hel ihc | #5 |
| akc disease | #5 |
| conjunctivitis pollen | #5 |
| allergic female | #5 |
| samples akc | #5 |
| conjunctivitis prostaglandin | #5 |
| crth2 prostaglandin receptors | #5 |
| ocular anesthesia | #5 |
| stained conjunctival | #5 |
| temperature blink | #5 |
| fibroblasts eosinophil adherence | #5 |
| lesion corneal | #5 |
| dryeye symptoms treatment | #5 |
| histamine superficial | #5 |
| eosinophil adhesion fibroblasts | #5 |
| simple papillary | #5 |
| hel cytokines | #5 |
| treatment epinastine | #5 |
| crth2 eosinophils | #5 |
| thinoptx iol | #5 |
| labeling surface akc | #5 |
| alterations ocular | #5 |
| papillae mucous | #6 |
| functions topical | #6 |
| severe vernal | #6 |
| eosinophil recruiting chemokines | #6 |
| ocular surface findings | #6 |
| akc refractory | #6 |
| hyperemia imidazoles | #6 |
| 4 9 genes | #6 |
| allergens cedrus | #6 |
| defect penetrating | #6 |
| dust asian | #6 |
| tear stability values | #6 |
| scores goblet | #6 |
| signs scored | #6 |
| tears xerophthalmia | #6 |
| twicedaily instillation | #6 |
| severe vkc | #6 |
| extract sterilized | #6 |
| regulation benzamidines | #6 |
| samples underwent | #6 |
| conjunctivitis sac | #6 |
| fibroblasts conjunctival | #6 |
| treatment postoperative inflammation | #6 |
| corneal fibroblasts pathogenesis | #6 |
| findings dry eye | #6 |
| oxidation hel | #6 |
| defect ped | #6 |
| 20 pbs | #6 |
| topical cys treatment | #6 |
| tranilast inhibition | #6 |
| july correlation | #6 |
| schirmer1 test values | #6 |
| topical levocabastine | #6 |
| inflammatory cell densities | #6 |
| symptoms vkc | #6 |
| hyperemia swelling | #6 |
| grading tear | #6 |
| obstructive mgd patients | #6 |
| diseases periostin | #6 |
| testing tear | #6 |
| corneal damage | #6 |
| topical cys | #6 |
| rose bengal dyes | #6 |
| eosinophils crth2 | #6 |
| dermatitis scored | #6 |
| ointment blood | #6 |
| pathogenesis ocular | #6 |
| coated elf | #6 |
| severe ocular inflammation | #6 |
| conjunctival confocal | #6 |
| concomitant eye | #6 |
| corneal temperature | #6 |
| tear eosinophil | #6 |
| conjunctival diseases | #6 |
| ocular fatigue | #6 |
| ecp markers | #6 |
| evaporation vital | #6 |
| strip meniscometry scores | #6 |
| sac vkc | #6 |
| tear meniscus patients | #6 |
| edema severity | #6 |
| akc vernal keratoconjunctivitis | #6 |
| intolerable irritation | #6 |
| controlling eyelid | #6 |
| tryptase proliferation | #6 |
| remodeling vkc | #6 |
| bengal vital stainings | #6 |
| cys ocular | #6 |
| sde ade | #6 |
| antiallergic eye | #6 |
| syndrome tablets | #6 |
| cgvhd improvements | #6 |
| agents interferometry | #6 |
| fva landolt | #6 |
| solution commercial | #6 |
| dressings female | #6 |
| allergic diathesis | #6 |
| allergic conjunctivitis cac | #6 |
| upper tarsal conjunctiva | #6 |
| patients seldi | #6 |
| rtpcr epithelial cells | #6 |
| tears acinar | #6 |
| eyes atopic | #6 |
| tbut vital | #6 |
| challenge cac | #6 |
| treatment tacrolimus | #6 |
| examinations tear | #6 |
| patients visante | #6 |
| dfna | #6 |
| female fluorometholone | #6 |
| atopic eyelids | #6 |
| itching conjunctival | #6 |
| density conjunctival | #6 |
| severe stevens | #6 |
| ade sde | #6 |
| il4 il2r | #6 |
| pcr muc5ac | #6 |
| differences tear | #6 |
| 4 muc | #6 |
| fluorometholone follow | #6 |
| cyclosporine 01 | #6 |
| instability conjunctival | #6 |
| induced tear | #6 |
| elevation refractory | #6 |
| specimens akc | #6 |
| noninvasive suction device | #6 |
| elasticity cutometer | #6 |
| tear ecp | #6 |
| rate tbut | #6 |
| levocabastine effective | #6 |
| levels air pollutants | #6 |
| chloride eye | #6 |
| betamethasone oral | #6 |
| tacrolimus chronic | #6 |
| conjunctival brush cytology | #6 |
| eye evaluated | #6 |
| silicone plugs | #7 |
| 4 tear | #7 |
| procedures radioimmunoassay | #7 |
| gpc vkc | #7 |
| vkc gpc | #7 |
| eyes ophthalmologists | #7 |
| conjunctival brush | #7 |
| cytology differ | #7 |
| nonparametric tears | #7 |
| tacrolimustreated eyes | #7 |
| conjunctiva brush | #7 |
| alpha tears | #7 |
| neutrophils corneal | #7 |
| tmh measurements | #7 |
| mucins periodic | #7 |
| eyelid surface | #7 |
| eczema frequently | #7 |
| ulcer corneal | #7 |
| cases preventing | #7 |
| ocular inflammatory disorder | #7 |
| conjunctivitis risk | #7 |
| inhibitor ono2235 | #7 |
| allergic eyelid | #7 |
| normal blinking | #7 |
| thought pathogenesis | #7 |
| solution bf | #7 |
| 10 clinical signs | #7 |
| rose bengal fluorescein | #7 |
| tears alpha | #7 |
| pgd2 dependent | #7 |
| suspension 01 | #7 |
| pge2 cox2 levels | #7 |
| injection oedema | #7 |
| ulceration healthy | #7 |
| prostaglandin atopic | #7 |
| age 325 years | #7 |
| ulcers revealed | #7 |
| conjunctivitis dry | #7 |
| western blotting nfκb | #7 |
| development allergic conjunctivitis | #7 |
| hyperemia adverse | #7 |
| superiority placebo | #7 |
| tear supply | #7 |
| conclusion mmc | #7 |
| meniscometry testing | #7 |
| papillae formation | #7 |
| hrtii rcm | #7 |
| pathogenesis subsequent | #7 |
| patients comfort level | #7 |
| nerves tear | #7 |
| improvements symptom scores | #7 |
| crth2 normal | #7 |
| incidence meibomian | #7 |
| sensation symptom | #7 |
| allergic dna | #7 |
| increases proliferative | #7 |
| necrotizing anterior | #7 |
| chemotaxis eosinophils | #7 |
| sensitization asian | #7 |
| attendance allergic | #7 |
| mmc observed | #7 |
| administration fluorescein | #7 |
| mucins tears | #7 |
| examination tear | #7 |
| collected brush | #7 |
| accommodating intraocular lens | #7 |
| surgery cooling | #7 |
| adult blepharitis | #7 |
| evaluation eyelid | #7 |
| sources chemokines | #7 |
| key prostaglandin | #7 |
| steroidal benzophenones | #7 |
| severe persistent cases | #7 |
| tacrolimus topical steroids | #7 |
| conjunctival inflammatory | #7 |
| conjunctival complications | #7 |
| amniotic membrane patching | #7 |
| tears th2 | #7 |
| mmc 005 | #7 |
| 0001 impression | #7 |
| corneal lesion | #7 |
| concentrations conjunctival | #7 |
| status atopic | #7 |
| revealed eosinophils | #7 |
| meniscometry scores | #8 |
| corneal epithelial lesions | #8 |
| 006 degree | #8 |
| blinking body | #8 |
| itching hyperemia | #8 |
| graticule scale | #8 |
| age 170 ± | #8 |
| alterations allergic | #8 |
| ihc hel | #8 |
| rollable intraocular | #8 |
| limbalbased conjunctival flap | #8 |
| stained hel | #8 |
| asia cats | #8 |
| eye redness | #8 |
| stainings schirmer | #8 |
| chemotaxis pgd2 | #8 |
| underwent tear | #8 |
| noninfectious corneal | #8 |
| microscopy conjunctival | #8 |
| brush cytology | #8 |
| surface teros | #8 |
| techniques keratoconjunctivitis | #8 |
| conjunctival findings | #8 |
| scores teros | #8 |
| tnfalpha eosinophils | #8 |
| teros values | #8 |
| corneal ulcer | #8 |
| pathogenesis test | #8 |
| trabeculectomy amniotic | #8 |
| sac akc | #8 |
| values slit | #8 |
| blink patients | #8 |
| il4 enzyme | #8 |
| patients vkc | #8 |
| conjunctivitis eyes | #8 |
| flare counts | #8 |
| par2 mast cells | #8 |
| keratocytes cytokines | #8 |
| meniscometry tear | #8 |
| ulcers detected | #8 |
| conjunctival sensation | #8 |
| akc patients controls | #8 |
| teros | #8 |
| corneal scores | #8 |
| oedema scores | #8 |
| correlation vital | #8 |
| expressions thought | #8 |
| mitomycin post | #8 |
| corneal fibroblasts tnfalpha | #8 |
| akc subjects | #8 |
| controls seldi | #8 |
| occlusion lacrimal | #8 |
| ccl5 conjunctiva | #8 |
| induced intraocular | #8 |
| fva measurements | #8 |
| blinking desiccation | #8 |
| hoc analysis study | #8 |
| betamethasone calcineurin | #8 |
| allergic dibenzazepines | #8 |
| radiation thermography | #8 |
| controls brush | #8 |
| staining hel | #8 |
| definite dry eye | #8 |
| superficial cells groups | #8 |
| diameter acinar | #8 |
| transient burning sensation | #8 |
| infrared radiation thermometry | #8 |
| patients corneal | #8 |
| fluorescein rose bengal | #8 |
| pollen odds | #8 |
| palpebral bulbar | #8 |
| classified allergic | #8 |
| 4 chemokines | #8 |
| alterations cornea | #8 |
| diagnosis conjunctivitis | #9 |
| mmc recurrence | #9 |
| hel 4 | #9 |
| level pollutants | #9 |
| pilocarpine tablets | #9 |
| tnfalpha fibroblasts | #9 |
| vital stainings | #9 |
| injection edema | #9 |
| smart eye | #9 |
| sufficient examination | #9 |
| sio2 pbs | #9 |
| cases conjunctivitis | #9 |
| prevalence vkc | #9 |
| design eyelid | #9 |
| prospective study tacrolimus | #9 |
| vital staining scores | #9 |
| stress staining | #9 |
| inflammation steroidal | #9 |
| pretreatment docosahexaenoic | #9 |
| operatedon eye | #9 |
| sensitivity conjunctival | #9 |
| cobblestone papillae | #9 |
| fatigue dry | #9 |
| patients tacrolimus treatment | #9 |
| received preserved | #9 |
| clinical ocular findings | #9 |
| severity corneal | #9 |
| tear level | #9 |
| hyperemia iop | #9 |
| differ allergic | #9 |
| crth2 expression eosinophils | #9 |
| tacrolimus 95 | #9 |
| pollution conjunctivitis | #9 |
| specular microscopic evaluation | #9 |
| diseases conjunctivitis | #9 |
| elisa tears | #9 |
| glaucoma younger age | #9 |
| conjunctivitis cases | #9 |
| 0001 schirmer | #9 |
| acid goblet | #9 |
| reductase cataract | #9 |
| fluorescein rose | #9 |
| sensitivity confocal | #9 |
| shield ulcers | #9 |
| prevalence weather | #9 |
| implantation 1cu | #9 |
| observed obstructive | #9 |
| pathogen allergic | #9 |
| excision intraoperative | #9 |
| tacrolimus treating | #9 |
| concentration tears | #9 |
| cys eye | #9 |
| subjective ocular | #9 |
| ono2235 | #9 |
| measurements vital | #9 |
| wash solution | #9 |
| tears thermography | #9 |
| foreign body sensation | #9 |
| untreated asian | #9 |
| histocytological study | #9 |
| supply superior | #9 |
| symptoms allergic conjunctivitis | #9 |
| eye normal subjects | #9 |
| genes cxc | #9 |
| eye grade | #9 |
| blood level tacrolimus | #9 |
| conjunctival fibroblast | #9 |
| superior limbic | #9 |
| patients ulcers | #10 |
| assessed conjunctival | #10 |
| laminin actins | #10 |
| staining oral | #10 |
| sensation ocular | #10 |
| bengal stainings | #10 |
| par2 mast | #10 |
| visante optical | #10 |
| diagnosis dry eye | #10 |
| conjunctivitis japan | #10 |
| scale tear | #10 |
| lower tmh | #10 |
| allergic bronchitis | #10 |
| conjunctival edema | #10 |
| vmr values | #10 |
| nonallergic conjunctivitis | #10 |
| conjunctivitis spring | #10 |
| measuring tear | #10 |
| iop hyperemia | #10 |
| icam1 tnfalpha | #10 |
| drugs conjunctival | #10 |
| conjunctivitis histamine | #10 |
| total tear ige | #10 |
| proliferation conjunctival | #10 |
| complain | #10 |
| cytometry il4 | #10 |
| humans mucin | #10 |
| punctal occlusion | #10 |
| substance tears | #10 |
| cornea eosinophils | #10 |
| treatment vkc | #10 |
| compared eyes | #10 |
| muc5ac muc16 | #10 |
| eye surface | #10 |
| functions dry | #10 |
| central graft | #10 |
| evaluation atopic | #10 |
| tears 10 | #10 |
| chemokines cxc chemokines | #10 |
| staining brush | #10 |
| produced conjunctival | #10 |
| humans conjunctival | #10 |
| improvement tear | #10 |
| incubated il4 | #10 |
| subbasal stromal | #10 |
| conjunctivitis atopic | #10 |
| status conjunctival | #10 |
| leupeptin benzamidine | #10 |
| layer alterations | #10 |
| crth2 chemotaxis | #10 |
| measurement strip | #10 |
| underwent slit | #10 |
| shield ulcer | #10 |
| allergic ocular | #10 |
| eye infrared | #10 |
| aged conjunctivitis | #10 |
| resection regrowth | #10 |
| eye clinically | #10 |
| insufficient local | #10 |
| allergic conjunctivitis spring | #10 |
| levels tears | #10 |
| ophthalmic adolescent | #10 |
| lacrimal puncta | #10 |
| topical cyclosporine patients | #10 |
| meibomian gland obstruction | #10 |
| muc16 muc5ac | #10 |
| tear cytology | #10 |
| count conjunctivitis | #11 |
| coherence dry | #11 |
| smart eye camera | #11 |
| sensation tear | #11 |
| weeks papillary | #11 |
| elicited statistically | #11 |
| levocabastine hydrochloride | #11 |
| amniotic membrane patch | #11 |
| test tear | #11 |
| lamp microscope | #11 |
| function ocular | #11 |
| common conjunctival | #11 |
| fibroblasts pathogenesis | #11 |
| vcam1 tnfalpha | #11 |
| vkc normal | #11 |
| surgery 13 eyes | #11 |
| cooling operation | #11 |
| diagnosis allergic | #11 |
| tears conjunctival | #11 |
| palpebral bulbar conjunctiva | #11 |
| ophthalmic solution | #11 |
| drop artificial | #11 |
| elisa il4 | #11 |
| initiation tacrolimus | #11 |
| cytometry oligonucleotide | #11 |
| landolt visual | #11 |
| vernal | #11 |
| therapy conjunctivitis | #11 |
| 1 month reduction | #11 |
| genes corneal | #11 |
| elasticity treatment | #11 |
| interleukin4 male | #11 |
| anesthesia strabismus | #11 |
| schirmer1 test | #11 |
| keratitis observed | #11 |
| preserved artificial | #11 |
| antivcaigg | #11 |
| sensation staining | #11 |
| hel hne | #11 |
| purpose metaplasia | #11 |
| higher muc1 | #11 |
| patient atopic | #11 |
| methods conjunctival | #11 |
| matched dry | #11 |
| vkc | #11 |
| prevalence dry eye | #11 |
| disease edition | #11 |
| vkc adolescent | #11 |
| vmr fva | #11 |
| association outpatient | #11 |
| eosinophils prostaglandin | #11 |
| mmhg elevation | #12 |
| patients sac | #12 |
| mgd controls | #12 |
| cornea density | #12 |
| conventional slit | #12 |
| microscopy efficient | #12 |
| selected severity | #12 |
| damage height | #12 |
| dermatitis tacrolimus | #12 |
| corneal shield | #12 |
| controls antibody titers | #12 |
| pemirolast potassium | #12 |
| density acinar | #12 |
| lacrimal punctal | #12 |
| fva vmr | #12 |
| immunologic rejection | #12 |
| iop glucocorticoids humans | #12 |
| conjunctival injection | #12 |
| highspeed highresolution | #12 |
| corneal aesthesiometry | #12 |
| density muc5ac | #12 |
| ulcers squamous | #12 |
| 1cu accommodating | #12 |
| 1cu iol | #12 |
| drugs pge2 | #12 |
| projects tears | #12 |
| expression 8 genes | #12 |
| acids chemokine | #12 |
| fva visual | #12 |
| levocabastine patients | #12 |
| fluorescein scores | #12 |
| supratarsal injection | #12 |
| coated lactoferrin | #12 |
| specimens eyes | #12 |
| surface diabetic | #12 |
| appearance atopic | #12 |
| radiography tears | #12 |
| 001 specimens | #12 |
| ccl11 conjunctiva | #12 |
| severe binocular | #12 |
| 002 ophthalmic | #12 |
| tears conjunctivitis | #12 |
| iop younger | #12 |
| leupeptins mast | #12 |
| receptor crth2 | #12 |
| keratoplasty glaucoma | #12 |
| extracts pollens | #12 |
| biomarker allergic | #12 |
| eye diagnosed | #12 |
| findings conjunctival | #12 |
| 1821 subjects | #12 |
| keratoconjunctivitis patients | #12 |
| aged disposable | #13 |
| 5ac ophthalmic | #13 |
| outcomes 01 | #13 |
| ulcers corneal | #13 |
| glaucoma keratoplasty | #13 |
| upper tarsal | #13 |
| bengal fluorescein | #13 |
| thirty eyes | #13 |
| suspensions tacrolimus | #13 |
| temperature cataract | #13 |
| conjunctival oedema | #13 |
| syndrome reactivation | #13 |
| vmr measurements | #13 |
| conclusions ocular | #13 |
| topical cyclosporine treatment | #13 |
| stability vital | #13 |
| objective signs | #13 |
| compared postsurgical | #13 |
| tear hel | #13 |
| scraped samples | #13 |
| dry eye examination | #13 |
| tear functions | #13 |
| symptoms conjunctival | #13 |
| interferometry tear | #13 |
| corneal complications | #13 |
| inflammation tear | #13 |
| epithelial disease | #13 |
| fluorometholone fml | #13 |
| sd105 | #13 |
| improvement vital | #13 |
| keratocytes incubated | #13 |
| anterior segment photography | #13 |
| months healed | #13 |
| cell flare | #13 |
| protein conjunctival | #13 |
| japan keratoconjunctivitis | #13 |
| papillary samples | #13 |
| coherence viscosupplements | #13 |
| called giant | #13 |
| remodeling relevant | #13 |
| blood levels tacrolimus | #13 |
| week corneal | #13 |
| chemokines stimulation | #13 |
| time fluorescein | #13 |
| glaucoma younger | #13 |
| applied operation | #13 |
| schirmers test values | #13 |
| specimens levels | #13 |
| treatment allergic conjunctivitis | #13 |
| 14 flare | #14 |
| conjunctival allergen challenge | #14 |
| dry eye controls | #14 |
| fluorometholone humans | #14 |
| conjunctival impression | #14 |
| eyes 002 | #14 |
| test rose | #14 |
| factors conjunctivitis | #14 |
| conjunctival muc5ac | #14 |
| functions corneal | #14 |
| density tear | #14 |
| bf 01 | #14 |
| secrete mediators | #14 |
| occlusion dry | #14 |
| fungi adolescent | #14 |
| mcfg treatment | #14 |
| solutions retrospective | #14 |
| flare count | #14 |
| clinically allergic | #14 |
| benzamidines blotting | #14 |
| cornea endophthalmitis | #14 |
| radioimmunoassay tears | #14 |
| vehicle eye | #14 |
| conjunctivitis vernal | #14 |
| conjunctivitis background | #14 |
| higher allergic | #14 |
| clinical corneal | #14 |
| schirmer1 | #14 |
| epithelial muc5ac | #14 |
| proliferative lesion | #14 |
| blinking patients | #14 |
| fibroblast damage | #14 |
| pilocarpine effective | #14 |
| visits allergic | #14 |
| rtpcr cytometry | #15 |
| examined existence | #15 |
| bromobenzenes child | #15 |
| olopatadine 01 | #15 |
| patients vernal | #15 |
| mmc female follow | #15 |
| investigated corneal | #15 |
| complications mmc | #15 |
| giant papillary | #15 |
| diseases 2020 | #15 |
| surface vital | #15 |
| expression realtime pcr | #15 |
| analysis par2 | #15 |
| topical 01 | #15 |
| ulcer echinocandins | #15 |
| corneal recurrence | #15 |
| receptor pgd2 | #15 |
| correlation tear | #15 |
| ocular itching | #15 |
| tmh values | #15 |
| improvement corneal | #15 |
| ophthalmology tokyo | #15 |
| adherence fibroblasts | #15 |
| ige ecp | #15 |
| tranilast anti | #15 |
| complications height | #15 |
| blepharitis conjunctivitis | #15 |
| evaluation conjunctival | #15 |
| ocular surface mucins | #15 |
| vkc methods | #15 |
| steroidal cornea | #15 |
| agents blepharitis | #15 |
| superior conjunctiva | #15 |
| improvement subjective symptoms | #15 |
| day bf | #15 |
| occlusion rose | #15 |
| ocular acrylic | #15 |
| occlusion oct | #15 |
| effects benzalkonium | #15 |
| mucous discharge | #15 |
| damaged fibroblasts | #15 |
| basal tear secretion | #15 |
| monitoring tear | #15 |
| cytology brush | #15 |
| eye drop treatment | #15 |
| irritation scores | #15 |
| bilateral conjunctivitis | #15 |
| firstline drug | #15 |
| safety 01 | #16 |
| assessment conjunctival | #16 |
| ari administration | #16 |
| objective ocular | #16 |
| patients vernal keratoconjunctivitis | #16 |
| ige correlation | #16 |
| odds ratio remission | #16 |
| fungi odds | #16 |
| segment photography | #16 |
| 2 conjunctival | #16 |
| temperature conjunctiva | #16 |
| eosinophils receptor | #16 |
| total clinical scores | #16 |
| alpha ortho | #16 |
| ulcers positive | #16 |
| female goblet | #16 |
| dust allergic | #16 |
| hours visit | #16 |
| treatment eyelid | #16 |
| reduction goblet | #16 |
| controls papillary | #16 |
| measurements tear | #16 |
| lacrimation | #16 |
| betamethasone induced | #17 |
| inflammation blotting | #17 |
| corneal sensation | #17 |
| analyzed 005 | #17 |
| inhibitor ari | #17 |
| ceramide gel | #17 |
| increased goblet cells | #17 |
| meniscometry | #17 |
| 20 normal patients | #17 |
| 13 females age | #17 |
| age dry | #17 |
| clearance corneal | #17 |
| staining muc1 | #17 |
| conjunctival samples | #17 |
| drops eyes | #17 |
| fibroblasts mcp1 | #17 |
| eyes schirmer | #17 |
| evaluation inflammatory | #17 |
| ocular allergic inflammation | #17 |
| muc16 mrna | #17 |
| wear soft | #17 |
| warmer treatment | #17 |
| signs ded | #17 |
| agents cedrus | #17 |
| initiation objective | #17 |
| expression eotaxin1 | #17 |
| strip meniscometry | #17 |
| fibroblasts damaged | #17 |
| sclera trabeculectomy | #17 |
| tnfα inflammatory response | #18 |
| technique glaucoma | #18 |
| intraoperative 002 | #18 |
| tear function | #18 |
| lower eyes | #18 |
| pollen fungi | #18 |
| higher tears | #18 |
| complete staining | #18 |
| types dry eye | #18 |
| inflammation lenses | #18 |
| concentrations corneal | #18 |
| trabeculectomy glaucoma | #18 |
| 30 ige | #18 |
| evaluation tear | #18 |
| differentiation inflammatory cells | #18 |
| conclusion ocular | #18 |
| ulceration subjects | #18 |
| induce corneal | #18 |
| studies rose | #18 |
| noncl wearers | #18 |
| ocular surface status | #18 |
| obstructive dysfunction | #18 |
| cd45 inflammatory | #18 |
| tear evaporation rate | #18 |
| associations level | #18 |
| bengal sjogren | #18 |
| correlation clinical signs | #18 |
| male ophthalmic solutions | #18 |
| cytology decrease | #18 |
| cytology corneal | #18 |
| rantes response | #18 |
| dibenzazepines dibenzoxepins | #18 |
| decrease ocular | #18 |
| groups spt | #18 |
| test tears | #18 |
| fibroblasts giant | #18 |
| ulcers compared | #18 |
| beta1 il1beta | #19 |
| steroid female | #19 |
| dha pretreatment | #19 |
| outpatient attendance | #19 |
| total signs | #19 |
| sodium 01 | #19 |
| temperature artificial | #19 |
| human conjunctival | #19 |
| subjects underwent | #19 |
| early efficacy | #19 |
| 1151 years | #19 |
| microscopy scans | #19 |
| sma performed | #19 |
| mitomycin ophthalmologic | #19 |
| measurements visante | #19 |
| aged ophthalmic | #19 |
| limbal allograft | #19 |
| effective tacrolimus | #19 |
| aged cautery | #19 |
| operation applied | #19 |
| prospective study eyes | #19 |
| inflammatory cells patients | #19 |
| staining scores | #19 |
| 3 severe | #19 |
| seldi proteinchip | #19 |
| evaluated infrared | #19 |
| vernal keratoconjunctivitis | #19 |
| eosinophils adhered | #19 |
| conjunctivitis topical | #19 |
| seldi analysis | #19 |
| periostin biomarker | #19 |
| ige tear | #19 |
| tears corneal | #20 |
| persistent epithelial defect | #20 |
| decreased conjunctival | #20 |
| surface findings | #20 |
| explain pathogenesis | #20 |
| conjunctivitis primary | #20 |
| patients strip | #20 |
| conclusion tacrolimus | #20 |
| conjunctivitis caused | #20 |
| proteins tears | #20 |
| evaluate noninferiority | #20 |
| pollen association | #20 |
| ulcers cell | #20 |
| treated 01 | #20 |
| plaques graded | #20 |
| symptoms allergic | #20 |
| height tmh | #20 |
| vernal keratoconjunctivitis vkc | #20 |
| summarized based | #20 |
| bilateral agerelated cataract | #20 |
| allergic female humans | #20 |
| corneal impression | #20 |
| 022 pg | #20 |
| improvements ocular | #20 |
| lower dry | #20 |
| mucin alterations | #20 |
| cytology upper | #20 |
| common ocular disorders | #20 |
| echinocandins eye | #20 |
| xerophthalmia adolescent | #20 |
| adhesion fibroblast | #21 |
| peripheral blood eosinophils | #21 |
| induced topical | #21 |
| ige groups | #21 |
| eye control | #21 |
| eye smaller | #21 |
| reduction topical | #21 |
| surface mucin | #21 |
| patients cedar | #21 |
| ocular symptoms signs | #21 |
| acuity assessment | #21 |
| keratoconjunctivitis atopic | #21 |
| cultured conjunctiva | #21 |
| conclusions topical | #21 |
| symptoms include | #21 |
| cornea clinical | #21 |
| preventing corneal | #21 |
| crth2 expressed | #21 |
| radiation thermometer | #21 |
| conjunctiva role | #21 |
| reaction tears | #21 |
| levels hel | #21 |
| patients concomitant treatment | #21 |
| lipid oxidative | #21 |
| eosinophils flow cytometry | #21 |
| microscopy patients | #21 |
| fluorescence postoperative | #21 |
| tears blood | #21 |
| film lipid | #21 |
| methane nonmethane hydrocarbons | #21 |
| therapies allergic | #22 |
| serum periostin patients | #22 |
| fluorescein staining | #22 |
| 005 topical | #22 |
| correlation humidity | #22 |
| epithelial lipid | #22 |
| eyes nerve | #22 |
| mgd adult | #22 |
| negative lower | #22 |
| haze photorefractive | #22 |
| flare anterior | #22 |
| fibroblasts anti | #22 |
| accommodation amplitude | #22 |
| 01 tacrolimus | #22 |
| types ocular | #22 |
| muc5ac patients | #22 |
| pge2 supernatants | #23 |
| prospectively surgery | #23 |
| diseases diclofenac | #23 |
| layer interferometry | #23 |
| solution compared | #23 |
| hrt confocal | #23 |
| disease atopic | #23 |
| corneal fluorescein | #23 |
| patients topical steroids | #23 |
| cooling applied | #23 |
| labeling tears | #23 |
| function mucin | #23 |
| 215 ± | #23 |
| blood concentration tacrolimus | #23 |
| il4 tnf | #23 |
| tests adenovirus | #23 |
| score deqs | #23 |
| lamp examinations | #23 |
| preschool conjunctivitis | #23 |
| 5 females | #23 |
| subjects squamous | #23 |
| solution corneal | #23 |
| palpebral conjunctiva | #23 |
| tear dynamics | #23 |
| 01 severe | #23 |
| local allergic reaction | #24 |
| formation allergic | #24 |
| interleukin4 oligonucleotide | #24 |
| control tear | #24 |
| tokyo dental | #24 |
| patients tacrolimus ointment | #24 |
| conjunctiva diabetes | #24 |
| ocular allergies | #24 |
| diseases web | #24 |
| histamine development | #24 |
| tarsal conjunctiva | #24 |
| surface tear | #24 |
| samples conjunctival | #24 |
| warming device | #24 |
| edema drug | #24 |
| dermatitis improved | #24 |
| layer tear | #24 |
| fungal corneal | #24 |
| bengal tears | #24 |
| 27yearold male patient | #24 |
| signs serum | #24 |
| vkc patients | #24 |
| cell meter | #24 |
| vital staining | #24 |
| antigen conjunctiva | #25 |
| vkc compared | #25 |
| slitlamp examinations | #25 |
| staining goblet | #25 |
| dynamics tear | #25 |
| 0001 dry | #25 |
| rtpcr rsv | #25 |
| bengal scores | #25 |
| atopic eosinophils humans | #25 |
| schedule eosinophil | #25 |
| steroid eye | #25 |
| level tears | #25 |
| eyes epithelial | #25 |
| corneal plaques | #25 |
| patients atopic diseases | #25 |
| rsv rtpcr | #25 |
| confocal prospective | #25 |
| protein rtpcr | #25 |
| density squamous | #25 |
| vcam1 activated | #25 |
| superficial cells | #25 |
| keratoconjunctivitis caused | #26 |
| eyes topical | #26 |
| 100 nylon | #26 |
| subjects measuring | #26 |
| 01 topical | #26 |
| level il4 | #26 |
| damage adhesion | #26 |
| smallincision cataract surgery | #26 |
| corneal ulcers | #26 |
| conclusions improvement | #26 |
| postkeratoplasty glaucoma | #26 |
| singletreatment groups | #26 |
| human α defensin | #26 |
| conjunctivitis | #26 |
| statistical decrease | #26 |
| solutions corneal | #26 |
| conjunctival inflammation | #26 |
| tbut tear | #26 |
| 005 immunoreactive | #26 |
| dmem f12 medium | #26 |
| lnfs | #26 |
| acinar unit | #26 |
| rapid epithelialization | #26 |
| slit lamp examinations | #26 |
| actins collagen | #26 |
| wheal diameter | #26 |
| aureus detected | #26 |
| symptoms itching | #26 |
| specific ige positivity | #26 |
| correlated corneal | #26 |
| adhered fibroblasts | #26 |
| treatment meibomian | #26 |
| diseases ambient | #26 |
| cytometry chemotaxis | #27 |
| 005 symptoms | #27 |
| 01 cyclosporine | #27 |
| alpha eosinophils | #27 |
| child cytological | #27 |
| associations prevalence | #27 |
| prescribed topical | #27 |
| oct prospective | #27 |
| therapy conjunctiva | #27 |
| conjunctival epithelial | #27 |
| epinastine | #27 |
| antibodies brush | #27 |
| eosinophils fibroblasts | #27 |
| factor exacerbation | #27 |
| lymphocytes specimens | #27 |
| density subbasal | #27 |
| interleukin4 polymerase | #27 |
| reaction sensation | #27 |
| tear ocular | #27 |
| prevalence allergic diseases | #28 |
| papillae patients | #28 |
| chemotactic activity eosinophils | #28 |
| conjunctival epithelial cells | #28 |
| il13 il1beta | #28 |
| solutions ophthalmologic | #28 |
| eosinophil adherence | #28 |
| assay eosinophils | #28 |
| underwent immunohistochemical | #28 |
| corneal vivo | #28 |
| conjunctiva dexamethasone | #28 |
| corneal ulceration | #28 |
| severe ocular | #28 |
| diseases proliferative | #28 |
| 4 5ac | #28 |
| assessment tear | #28 |
| ophthalmic | #28 |
| provide relief | #28 |
| objective scores | #28 |
| giant papillae | #28 |
| 2 iol | #28 |
| stress atopic | #28 |
| rosebengal | #29 |
| aged thermography | #29 |
| studies conjunctivitis | #29 |
| numbers inflammatory | #29 |
| performed morphometric | #29 |
| conjunctiva dose | #29 |
| ketotifen fumarate | #29 |
| flare cell | #29 |
| inhibited tranilast | #29 |
| 5ac mucins | #29 |
| allergic regulation | #29 |
| scores schirmer | #29 |
| disease periostin | #29 |
| sac compared | #29 |
| eye mask | #29 |
| cys treatment | #29 |
| corneal conjunctival | #29 |
| thermography adolescent | #29 |
| il2r serum | #30 |
| inhibitors pollen | #30 |
| conjunctivitis patients | #30 |
| dermatitis efficacy | #30 |
| infection conjunctival | #30 |
| expressed crth2 | #30 |
| redness eye | #30 |
| tear serum | #30 |
| ocular surface alterations | #30 |
| common adverse reaction | #30 |
| recruitment day | #30 |
| palpebral | #30 |
| symptoms accompanying | #30 |
| effective artificial | #30 |
| regrowth observed | #30 |
| mucins ophthalmic | #30 |
| conjunctiva cells | #30 |
| conjunctivitis humans | #30 |
| eye common | #30 |
| fibroblasts protease | #30 |
| minutes visit | #30 |
| specificity tears | #30 |
| syndromes equipment | #30 |
| tear ige | #30 |
| atopic diagnostic | #30 |
| vegf cultured | #31 |
| levels july | #31 |
| schirmer scores | #31 |
| expressed eosinophils | #31 |
| dermatitis purpose | #31 |
| meibomian gland secretion | #31 |
| scores corneal | #31 |
| disease summarized | #31 |
| fibroblasts pcr | #31 |
| combinations eosinophils | #31 |
| neutrophils severity | #31 |
| properties tears | #31 |
| pathogenesis corneal | #31 |
| hel levels | #31 |
| ige negative | #31 |
| worse observed | #31 |
| acuity fva | #31 |
| epithelial mucins | #31 |
| atopic 10 | #31 |
| inflammation atopic | #31 |
| signs improved | #32 |
| diagnosed dry | #32 |
| analysis tears | #32 |
| conjunctival cells | #32 |
| keratoconjunctivitis | #32 |
| tear meniscus height | #32 |
| limbus cornea | #32 |
| tgfbeta1 il1beta | #32 |
| substantial interrater agreement | #32 |
| eye sjögren | #32 |
| reduced steroid | #32 |
| sign scores | #32 |
| deqs | #32 |
| schirmer test values | #32 |
| western blotting effects | #32 |
| expressibility | #32 |
| prostaglandin cell | #32 |
| count prostaglandin | #33 |
| signs evaluated | #33 |
| haze score | #33 |
| conclusions confocal | #33 |
| ige histamine | #33 |
| levocabastine | #33 |
| allergic double | #33 |
| 4 grades | #33 |
| edema correlated | #33 |
| immunoglobulin interferometry | #33 |
| film break | #33 |
| atopic skin disease | #33 |
| visante | #33 |
| muc 1 | #33 |
| seasonal young | #33 |
| numbers quantitative | #33 |
| iop induced | #33 |
| bengal staining | #34 |
| alpha fibroblasts | #34 |
| proteinchip array | #34 |
| fibroblasts purpose | #34 |
| treatment mgd | #34 |
| fluorometholone glucocorticoids | #34 |
| il1beta tgfbeta1 | #34 |
| intraocular pressure surgery | #34 |
| eye 10 | #34 |
| 01 effective | #34 |
| therapy histamine | #34 |
| conjunctiva cytokines | #34 |
| clinical signs patients | #34 |
| 10 objective | #34 |
| eyes corneal | #34 |
| mucins prospective | #35 |
| adult asthenopia | #35 |
| cyclosporine cys | #35 |
| 6 months conclusion | #35 |
| interrater reproducibility | #35 |
| tear stability | #35 |
| virus capsid antigen | #35 |
| hypertension tacrolimus | #35 |
| eye 20 | #35 |
| objective symptoms | #35 |
| ocular surface inflammation | #36 |
| functional visual acuity | #36 |
| schirmer 1 | #36 |
| humans keratoconjunctivitis | #36 |
| differential dry | #36 |
| efficacy groups | #36 |
| tear samples | #36 |
| anterior scleritis | #36 |
| eyes acrysof | #36 |
| resection 005 | #36 |
| severe allergic | #36 |
| diseases eosinophil | #36 |
| measured tear | #36 |
| vdt users | #36 |
| tear clearance | #36 |
| tears tumor | #37 |
| tacrolimus 12 | #37 |
| oct effective | #37 |
| eyelid skin | #37 |
| conducted compliance | #37 |
| recurrence corneal | #37 |
| delefilcon | #37 |
| schirmer 1 test | #37 |
| contact lens surface | #37 |
| tenon anesthesia | #37 |
| wellrecognized risk | #37 |
| laser flarecell meter | #37 |
| scleritis episcleritis | #37 |
| 002 mmc | #37 |
| induced iop | #37 |
| aged olopatadine | #38 |
| gland lipid | #38 |
| device eye | #38 |
| allergic cromolyn | #38 |
| exhibited correlation | #38 |
| cac japanese | #38 |
| 002 mitomycin | #38 |
| pemirolast | #38 |
| phacoemulsification implantation | #38 |
| post cataract | #38 |
| response pretreatment | #39 |
| infiltration corneal | #39 |
| cells conjunctiva | #39 |
| tests diagnostic accuracy | #39 |
| solutions patient | #39 |
| tears eye | #39 |
| degree 20 | #39 |
| conjunctiva limbus | #39 |
| 005 oct | #39 |
| patients dry eye | #39 |
| 0001 specimens | #39 |
| cyclosporine dry | #39 |
| accommodating intraocular | #39 |
| atopic dry | #39 |
| tmh | #40 |
| pharmacology clinical efficacy | #40 |
| drops corneal | #40 |
| samples eyes | #40 |
| decreased inflammation | #40 |
| acid chemokine | #40 |
| biomarkers conjunctiva | #40 |
| endothelial rejection | #40 |
| ulcers control | #40 |
| subjects specimens | #40 |
| eye patients | #40 |
| eyes superior | #41 |
| treated topical | #41 |
| epitheliopathy | #41 |
| α pge2 | #41 |
| il1beta vegf | #41 |
| homologous visual | #41 |
| ecp concentrations | #41 |
| treatment dry | #41 |
| vegf il1beta | #41 |
| pollution severe | #41 |
| stimulate vascular | #41 |
| conjunctivitis gpc | #41 |
| allergens conjunctivitis | #42 |
| break time | #42 |
| day eye | #42 |
| scans underwent | #42 |
| efficient noninvasive | #42 |
| october july | #42 |
| corneal epithelia | #42 |
| limbus corneal | #43 |
| keratolimbal | #43 |
| revised 2010 | #43 |
| rollable | #43 |
| hydrocarbons data | #43 |
| instability decreased | #43 |
| cytology revealed | #43 |
| microscopy central | #43 |
| diseases 2017 | #43 |
| eyelid edema | #43 |
| surface years | #43 |
| meniscus treatment | #43 |
| conjunctival hyperemia | #43 |
| tacrolimus treatment | #44 |
| patients rhinoconjunctivitis | #44 |
| subjective symptom | #44 |
| oct assessment | #44 |
| agents keratoconjunctivitis | #44 |
| il1beta il4 | #44 |
| tear meniscus | #44 |
| tryptase par2 | #44 |
| elasticity patients | #44 |
| abovementioned drugs | #44 |
| activated il4 | #44 |
| eye 0001 | #44 |
| collagens fibronectin | #44 |
| cautery female | #44 |
| epithelial defect | #44 |
| recruiting chemokines | #45 |
| body sensation | #45 |
| fibroblasts expression | #45 |
| 24 seconds | #45 |
| inflammation ocular surface | #45 |
| adult chemotaxis | #45 |
| case corneal | #45 |
| laser microscopy | #45 |
| fibroblasts eosinophils | #45 |
| elevation iop | #45 |
| users contact | #45 |
| signs score | #45 |
| bovine enteric | #45 |
| japan particulate | #45 |
| metaplasia grade | #45 |
| micafungin mcfg | #45 |
| metaplasia mucin | #45 |
| superficial punctate keratitis | #45 |
| surgery uncorrected | #45 |
| correlation inflammation | #45 |
| fourgrade scale | #45 |
| formation corneal | #45 |
| understanding ocular | #45 |
| graded 3 | #45 |
| surface inflammation | #45 |
| rose bengal staining | #45 |
| topical tacrolimus treatment | #45 |
| tryptases regulation | #46 |
| status ocular | #46 |
| staining inflammatory | #46 |
| seconds controls | #46 |
| efficacy combined therapy | #46 |
| surface disease | #46 |
| graticule | #46 |
| corneal cells | #46 |
| il13 serum | #46 |
| fluorometholone | #46 |
| suspension effective | #46 |
| 17 japanese patients | #46 |
| efficacy 01 | #46 |
| posttreatment findings | #46 |
| staining conjunctival | #46 |
| conjunctival | #46 |
| rate ocular | #47 |
| diameter plant | #47 |
| blood level | #47 |
| ulcer score | #47 |
| visante oct | #47 |
| allergic female histamine | #47 |
| positive muc5ac | #47 |
| purpose efficacy | #47 |
| patients 01 | #47 |
| suspension 4 | #47 |
| cyclosporine ophthalmic | #48 |
| sac patients | #48 |
| enhanced benefits | #48 |
| brush cytology specimens | #48 |
| complications corneal | #48 |
| dexamethasone anti | #48 |
| stimulation chemokine | #48 |
| stromal nerve | #48 |
| muc5ac mrna | #48 |
| implantation acrysof | #48 |
| eyes month | #48 |
| eyelid warming | #48 |
| 1cu | #49 |
| fibroblasts incubated | #49 |
| male tears | #49 |
| cxc chemokine genes | #49 |
| concentrations tears | #49 |
| adult ca125 | #49 |
| eosinophils epithelium | #49 |
| ocular signs | #49 |
| objective findings | #49 |
| expression crth2 | #49 |
| tacrolimus female | #49 |
| visits air | #49 |
| keratocytes fibroblasts | #49 |
| trabeculectomy eyes | #49 |
| dyes fluorophotometry | #50 |
| 4 normal controls | #50 |
| disposable soft | #50 |
| schirmers test | #50 |
| ulcers purpose | #50 |
| inflammation conjunctiva | #50 |
| total severity score | #50 |
| patient eyes | #50 |
| test ocular | #50 |
| aged blinking | #50 |
| measuring corneal | #50 |
| meniscus height | #50 |
| decreased tear | #50 |
| trabeculectomy mitomycin | #50 |
| lenses scls | #51 |
| inflammation cataract | #51 |
| periostin patients | #51 |
| ocular surface cells | #51 |
| reduction score | #51 |
| diagnosis dry | #51 |
| members japan | #51 |
| crth2 expression | #51 |
| scls | #51 |
| markers atopic | #51 |
| cells brush | #51 |
| effects docosahexaenoic acid | #51 |
| severity objective | #52 |
| atopic groups | #52 |
| biomarker diseases | #52 |
| month initiation | #52 |
| examination parameters | #52 |
| stability corneal | #52 |
| reaction vehicle | #52 |
| eyelid margins | #52 |
| inflammation decline | #52 |
| tears tomography | #52 |
| pcr tgf | #52 |
| eye normal | #52 |
| stromal nerves | #53 |
| acuity values | #53 |
| bromfenac | #53 |
| differential eosinophil | #53 |
| chloride bak | #54 |
| suspension treatment | #54 |
| vegf protein secretion | #54 |
| 005 month | #54 |
| limbic keratoconjunctivitis | #54 |
| lacrimal glands | #54 |
| obstructive mgd | #54 |
| presence rsv | #54 |
| scores tear | #54 |
| oxidation adolescent | #54 |
| conjunctiva drug | #55 |
| aged pollen | #55 |
| surface clinical | #55 |
| epithelial cells expression | #55 |
| adult conjunctivitis | #55 |
| combinedtreatment | #55 |
| atopic enterotoxins | #55 |
| ocular signs symptoms | #55 |
| antagonists allergic | #55 |
| local cytokine production | #55 |
| specular microscopic | #56 |
| dysfunction atopic | #56 |
| cornea cyclooxygenase | #56 |
| mechanism giant | #56 |
| eosinophil cationic | #56 |
| ded adult | #56 |
| pain photophobia | #56 |
| mucin layer | #56 |
| plant pollens | #56 |
| mucin2 mucin4 | #56 |
| topical adolescent | #56 |
| solution placebo | #56 |
| film ocular | #56 |
| 3 dry | #56 |
| atopic patients | #56 |
| allergies adolescent | #56 |
| penetrating limbus | #57 |
| chemotactic responses | #57 |
| accommodating iol | #57 |
| humans interleukin4 | #57 |
| insensible administration | #57 |
| giant papillary conjunctivitis | #57 |
| inflammation pge2 | #57 |
| maximum blood concentration | #58 |
| drop treatment | #58 |
| seventyeight eyes | #58 |
| schiff staining | #58 |
| papilla formation | #58 |
| staining tear | #58 |
| objective sign | #58 |
| alpha defensins | #58 |
| intraoperative mitomycin | #59 |
| disease eyes | #59 |
| tear instability | #59 |
| pm25 prevalence | #59 |
| type allergic | #59 |
| findings criteria | #59 |
| signs severe | #60 |
| release inhibitor | #60 |
| mmc 2 | #60 |
| evaluation items | #60 |
| compared 0001 | #60 |
| syndromes female | #60 |
| daily disposable | #60 |
| diabetic corneal | #60 |
| pcr severe | #60 |
| tacrolimus ointment treatment | #60 |
| correlation patients | #61 |
| thermography adult | #61 |
| nonsteroidal blotting | #61 |
| punctal | #61 |
| eyes 16 | #62 |
| total clinical | #62 |
| combination epithelium | #62 |
| specimens histopathologic | #62 |
| values tended | #62 |
| amplitude accommodation | #62 |
| expression eyes | #62 |
| eotaxin1 expression | #62 |
| allergen mediated | #62 |
| prostaglandin patients | #62 |
| ulcer endophthalmitis | #63 |
| chamber body | #63 |
| patient corneal | #63 |
| conjunctiva patients | #63 |
| corneal erosion | #63 |
| corneal stem | #63 |
| micafungin treatment | #63 |
| il4 role | #63 |
| hypersensitivity japan | #63 |
| oral pilocarpine | #63 |
| sac age | #63 |
| radioimmunoassay respiratory | #64 |
| cornea dry | #64 |
| il4 culture | #64 |
| evaluation corneal | #64 |
| positive mucin | #64 |
| dexamethasone production | #64 |
| density inflammatory | #64 |
| factor allergic | #64 |
| eye adolescent | #64 |
| dust house | #65 |
| microscope methods | #65 |
| conclusions corneal | #65 |
| live rsv | #65 |
| tears biomarkers | #65 |
| mucins rna | #65 |
| viral radioimmunoassay | #65 |
| treatment immunosuppressive agents | #66 |
| surface epithelial | #66 |
| cases atopic | #66 |
| diagnosis therapies | #66 |
| layer speed | #66 |
| 003 treatment | #67 |
| cyclosporine eye | #67 |
| persistent epithelial | #67 |
| female fluorophotometry | #67 |
| agents keratoplasty | #67 |
| period oral | #67 |
| effects 01 | #67 |
| ointment treatment | #68 |
| housedust | #68 |
| time vital | #68 |
| eye dry | #68 |
| occlusion 005 | #69 |
| fibroblasts corneal | #69 |
| counter drugs | #69 |
| aged tears | #69 |
| ophthalmic solutions | #69 |
| glaucoma graft | #69 |
| patients eosinophils | #69 |
| fibroblasts examined | #69 |
| 22 eyes | #70 |
| crth2 receptor | #70 |
| values rose | #70 |
| crth2 pgd2 | #70 |
| 1436 patients | #70 |
| rhinoconjunctivitis allergic | #70 |
| schirmer test | #70 |
| visit 4 | #70 |
| allergic dermatitis | #71 |
| drops treatment | #71 |
| lenses dry | #71 |
| factors tears | #71 |
| dust 20 | #71 |
| 16 eyes | #72 |
| tear production | #72 |
| ige eosinophil | #72 |
| bulbar conjunctiva | #72 |
| glaucoma trabeculectomy | #72 |
| epithelial structure | #73 |
| immunosuppressive treatment patients | #73 |
| extraction conjunctiva | #73 |
| surface mucins | #73 |
| fml | #73 |
| punctate keratopathy | #73 |
| antiallergic agent | #73 |
| fluorophotometry humans | #73 |
| liquid conjunctiva | #73 |
| pyridines pyrimidinones | #73 |
| pollution prevalence | #73 |
| evaluation dry | #74 |
| eosinophils expressed | #74 |
| mcfg | #74 |
| tacrolimus patients | #74 |
| iol acrysof | #74 |
| inflammatory cell numbers | #74 |
| agents intraocular | #74 |
| pilocarpine prospective | #75 |
| cedar pollen | #75 |
| dust epidemiologic | #75 |
| healthy individuals patients | #75 |
| improved infrared | #75 |
| laser flare | #75 |
| completely controlled | #75 |
| 1 month baseline | #75 |
| agents interleukin4 | #76 |
| guidelines allergic | #76 |
| interleukin4 rna | #76 |
| ccchemokine | #76 |
| excision recurrence | #77 |
| lower tear | #77 |
| capilia | #77 |
| cytokines stimulate | #77 |
| chemical mediator | #77 |
| slight elongation | #77 |
| vegf tgfbeta1 | #77 |
| cornea module | #77 |
| ophthalmological elasticity | #77 |
| studies suspensions | #77 |
| surgery technique | #77 |
| cytology samples | #77 |
| signs treatment | #77 |
| concentration il2 | #78 |
| signs observed | #78 |
| severity ocular | #78 |
| concomitant tacrolimus | #78 |
| pollen compared | #78 |
| drops 1 | #78 |
| japanese guideline | #78 |
| effects corneal | #79 |
| type allergy | #79 |
| ocular pain | #79 |
| injection reduction | #79 |
| glaucoma penetrating | #79 |
| permeability cornea | #79 |
| dry eye | #79 |
| allergic environmental | #79 |
| extended wear | #79 |
| il4 ige | #79 |
| inhibitors leupeptin | #79 |
| medications required | #80 |
| questionnaires tears | #80 |
| mgd patients | #80 |
| mediated par2 | #80 |
| assay epithelial | #80 |
| antigens histamine | #81 |
| vegf concentration | #81 |
| decreased dry | #81 |
| acrysof iol | #82 |
| atopic dermatitis study | #82 |
| caused insufficient | #82 |
| patients conjunctivitis | #82 |
| prostaglandin reverse | #82 |
| cytology performed | #82 |
| data tacrolimus | #83 |
| tear lipid | #83 |
| dental college | #83 |
| complications lenses | #83 |
| expression corneal | #83 |
| patients staphylococcus aureus | #83 |
| papillae | #84 |
| schirmer | #84 |
| cytokines vegf | #84 |
| correlation corneal | #84 |
| earlier published data | #84 |
| epithelium ocular | #84 |
| 5 grades | #85 |
| temperature patients | #85 |
| treatment odds ratio | #85 |
| patients dry | #85 |
| human reverse | #85 |
| inhibitors tryptases | #85 |
| scleritis patients | #85 |
| 18 pg | #85 |
| combined penetrating | #85 |
| hyperemia induced | #85 |
| alterations basal | #85 |
| inflammation eye | #86 |
| acuity accommodation | #86 |
| 284 years | #86 |
| patients eyelid | #86 |
| pharmacologic intervention | #86 |
| sligkv | #86 |
| discharge evaluated | #86 |
| daily outpatient | #86 |
| edema scores | #86 |
| tacrolimus young | #87 |
| detection limit assay | #87 |
| confocal ophthalmic | #87 |
| tacrolimus reduced | #87 |
| cells keratocytes | #88 |
| post keratoplasty | #88 |
| tears | #88 |
| sclera surgical | #88 |
| regulation muc5ac | #88 |
| disease conjunctiva | #88 |
| daily weather conditions | #88 |
| tears visual | #89 |
| assessment dry | #89 |
| tryptase inhibitors | #89 |
| findings severe | #89 |
| seasonal perennial | #89 |
| eyes 30 | #89 |
| early ocular | #90 |
| glands microscopy | #90 |
| dressings chronic | #90 |
| tears adult | #90 |
| cytocentrifuge preparations | #90 |
| lower corneal | #90 |
| temperature cornea | #90 |
| decrease corneal | #90 |
| months signs | #90 |
| film breakup | #91 |
| lenses extended | #91 |
| techniques trabeculectomy | #92 |
| laser cell | #92 |
| eye corneal | #92 |
| exposure japan | #92 |
| procedures phacoemulsification | #92 |
| drug fibroblasts | #93 |
| tears administration | #93 |
| eye cataract surgery | #93 |
| 005 complications | #93 |
| stromal corneal | #93 |
| regulation muc1 | #93 |
| solutions tears | #93 |
| patients correlation | #93 |
| preschool conjunctiva | #93 |
| treatment noninfectious | #93 |
| 7 visit | #93 |
| conjunctival specimens | #93 |
| pollution weather | #94 |
| reaction physical | #94 |
| exposure exhaust | #94 |
| classification pathogenesis | #94 |
| pgd2 crth2 | #94 |
| case allergic | #94 |
| relevant factor | #95 |
| eosinophils patients | #95 |
| studies tears | #95 |
| twentyeight eyes | #95 |
| eye higher | #95 |
| induced pgd2 | #95 |
| staining fluorescein | #96 |
| study cyclosporine | #96 |
| protein eosinophilia | #96 |
| higher eyes | #96 |
| score objective | #96 |
| 128 eyes | #96 |
| 1month treatment | #97 |
| cells hel | #97 |
| production pge2 | #97 |
| treatment ecp | #97 |
| 4 alterations | #97 |
| eye tear | #98 |
| staining schirmer | #98 |
| eyes study | #98 |
| eyes positive | #98 |
| meniscus patients | #98 |
| vdts | #98 |
| japan post | #99 |
| management ocular | #99 |
| surgery 6 months | #99 |
| cytology evaluation | #99 |
| 005 recurrence | #99 |
| pseudophakic patients | #99 |
| solution improved | #99 |
| equivalent 4 | #99 |
| corneal abnormalities | #100 |
| cells severity | #100 |
| local pattern | #100 |
| allergic atopic | #100 |
| postoperatively statistically | #100 |
| conjunctiva corneal | #100 |
| ointments tacrolimus | #100 |
| confocal scanning | #100 |
| ulcer patient | #100 |
| terminals contact | #100 |
| pathogenesis atopic | #101 |
| eyes 10 | #101 |
| fibroblasts 2 | #101 |
| effects tranilast | #102 |
| keratolimbal allograft | #102 |
| therapy conjunctival | #102 |
| agents conjunctivitis | #102 |
| severe atopic | #102 |
| disease classified | #102 |
| pathogenesis allergic | #102 |
| mediated protease | #103 |
| chemotaxis experiments | #103 |
| washing solution | #103 |
| prevalence dry | #103 |
| subjective comfort | #103 |
| topical cyclosporine | #104 |
| allergic cytokines | #104 |
| syndrome epstein | #104 |
| events scores | #104 |
| groups dry | #104 |
| differences ocular | #104 |
| tears young | #104 |
| topic premedication | #104 |
| values vital | #104 |
| patients bf | #104 |
| conjunctival impression cytology | #105 |
| role staphylococcal | #105 |
| child conjunctival | #105 |
| baseline initiation | #105 |
| aged amnion | #105 |
| wearing contact | #105 |
| inflammation diagnosis | #105 |
| parameters ocular | #106 |
| adhesion fibroblasts | #106 |
| 14 eyes | #106 |
| pressure keratoplasty | #106 |
| microscopy evaluation | #106 |
| conjunctiva cornea | #106 |
| corneal keratocytes | #107 |
| patients ded | #107 |
| superficial punctate | #107 |
| eotaxin1 | #107 |
| dry mouth symptoms | #108 |
| film instability | #108 |
| acuity acrylic | #108 |
| topical tacrolimus | #108 |
| levels radioimmunoassay | #108 |
| scores symptoms | #108 |
| resins aged | #108 |
| induces chemotaxis | #108 |
| lipid layer | #108 |
| conjunctiva | #108 |
| effects dha | #109 |
| tear evaporation | #109 |
| corneal inflammatory | #109 |
| il4 human | #109 |
| 4 dry | #109 |
| asian dust | #109 |
| level tacrolimus | #109 |
| increased evaporation | #110 |
| japanese guidelines | #110 |
| eyes 9 | #110 |
| conjunctival epithelium | #110 |
| steroids administration | #110 |
| controls inflammatory | #110 |
| lacrimal salivary | #110 |
| dysfunction mgd | #110 |
| topical instillation | #111 |
| severity markers | #111 |
| vcam1 antibody | #112 |
| eye camera | #112 |
| strabismus surgery | #113 |
| pcr rsv | #113 |
| papillary conjunctivitis | #113 |
| solutions platelet | #113 |
| dibenzoxepins | #113 |
| anterior segment inflammation | #113 |
| layer patients | #114 |
| incision cataract | #114 |
| lesions atopic | #114 |
| diagnosed allergic | #114 |
| eye irritation | #114 |
| grading scores | #114 |
| allergic eye | #115 |
| findings severity | #115 |
| 13 eyes | #115 |
| sjögrens syndrome patients | #115 |
| goblet cell density | #115 |
| cholinergic treatment | #115 |
| seconds 0001 | #115 |
| male mucin | #115 |
| conjunctival cell | #115 |
| selective histamine | #116 |
| edition revised | #116 |
| metaplasia mucins | #117 |
| cooling increased | #117 |
| asia dust | #117 |
| patients seasonal | #117 |
| ophthalmology prevalence | #117 |
| samples stained | #117 |
| viscosupplements aged | #117 |
| immunologic receptors prostaglandin | #118 |
| effects docosahexaenoic | #118 |
| sag genes | #118 |
| generation pge2 | #118 |
| molecule1 interleukin4 | #118 |
| week 005 | #119 |
| skin elasticity | #119 |
| 39 mmhg | #119 |
| chemotaxis induced | #119 |
| revealed higher | #119 |
| topical steroids | #119 |
| iop observed | #119 |
| acuity distance | #119 |
| syndromes epithelium | #120 |
| matter prevalence | #120 |
| levels histamine | #121 |
| mitomycinc mmc | #121 |
| distance corrected | #121 |
| mitomycin ophthalmic | #121 |
| soft lenses | #121 |
| chronic allergic | #122 |
| artificial tear | #123 |
| adult conjunctiva | #123 |
| titers ebv | #123 |
| male ointments | #123 |
| collagen conjunctiva | #123 |
| eosinophils cell | #124 |
| area corneal | #124 |
| conjunctival tissues | #125 |
| activity corneal | #125 |
| month reduced | #126 |
| damage severe | #126 |
| proteaseactivated receptor2 | #126 |
| patients atopic | #127 |
| 05ng | #127 |
| nerves studied | #127 |
| subjects vivo | #127 |
| soft contact lenses | #128 |
| gamma increase | #128 |
| 9 genes | #128 |
| 361 ± | #129 |
| acds | #129 |
| combination steroids | #129 |
| elisa levels | #129 |
| fibroblast viability | #129 |
| fva | #130 |
| functional visual | #130 |
| patients insignificant | #130 |
| disease cornea | #131 |
| antigen hladr | #131 |
| management allergic | #132 |
| resection severe | #132 |
| eye drop | #132 |
| cataract phacoemulsification | #132 |
| eyes fluorescein | #132 |
| 5ac | #132 |
| treated tacrolimus | #133 |
| keratoplasty adult | #133 |
| 19 normal subjects | #133 |
| skin water | #133 |
| gene transcription levels | #133 |
| proteins mucin | #133 |
| density negative | #134 |
| acrylic iol | #134 |
| normal conjunctival | #134 |
| surface examination | #134 |
| pcr hla | #134 |
| specimens vivo | #135 |
| solutions phacoemulsification | #135 |
| stress status | #136 |
| iop treatment | #136 |
| ophthalmological dry | #137 |
| severity 10 | #137 |
| antiallergic properties | #137 |
| eosinophil adhesion | #137 |
| dry eye patients | #137 |
| ocular surface | #137 |
| asian dust storms | #138 |
| eosinophil cationic protein | #138 |
| iol groups | #138 |
| protein ecp | #139 |
| authors technique | #139 |
| ratio remission | #139 |
| allergic dogs | #139 |
| suppressed pretreatment | #140 |
| aminobenzoates anti | #141 |
| allergic patients | #141 |
| inflammation prostaglandin | #141 |
| improvements symptom | #142 |
| interleukin1 interleukin13 | #142 |
| findings upper | #142 |
| olopatadine hydrochloride | #143 |
| combination rapid | #143 |
| determine central | #144 |
| cornea cyclosporine | #144 |
| studies scleritis | #144 |
| 52 mmhg | #144 |
| symptoms ocular | #145 |
| eye syndromes | #145 |
| recordable | #145 |
| specimens patient | #145 |
| human conjunctiva | #146 |
| schiff reaction | #146 |
| reticular basement membrane | #146 |
| underwent evaluation | #146 |
| eye clinical | #146 |
| fibroblasts alpha | #146 |
| virus pathogen | #146 |
| findings adolescent | #146 |
| impression cytology | #147 |
| required type | #147 |
| 263 years | #147 |
| dscg | #147 |
| hne 4 | #147 |
| diagnosis atopic | #147 |
| ulcer drug | #148 |
| dynamic visual acuity | #148 |
| 0001 corneal | #148 |
| increased goblet | #148 |
| patients allergic | #149 |
| japan phenotype | #149 |
| suspension based | #149 |
| quantitative evaluation | #149 |
| fibroblasts production | #149 |
| concentration tacrolimus | #149 |
| intraocular lens iol | #149 |
| cationic protein | #149 |
| pyrimidinones treatment | #150 |
| inflammatory cells | #150 |
| japanese cedar pollen | #150 |
| controls performed | #151 |
| inflammation reduction | #151 |
| postoperative secondary | #152 |
| par2 reverse | #152 |
| tacrolimus treated | #152 |
| induced eotaxin | #153 |
| symptoms objective | #153 |
| artificial tears | #153 |
| increased fibroblasts | #153 |
| 28 surgery | #153 |
| eyes 11 | #153 |
| concentrations il4 | #154 |
| grade effects | #155 |
| inflammation ocular | #155 |
| male mitomycin | #155 |
| chemokine expression | #156 |
| association pm25 | #156 |
| eyelids female | #156 |
| alcon | #156 |
| pcr increase | #157 |
| greater inflammation | #157 |
| rates untreated | #157 |
| analysis prostaglandin | #157 |
| values improved | #157 |
| inflammatory ocular | #157 |
| ointments skin | #157 |
| lipid infiltration | #157 |
| acuities | #158 |
| trial tacrolimus | #158 |
| surface status | #158 |
| japan included | #158 |
| weeks adverse | #159 |
| immunological characteristics | #159 |
| 3 boys | #159 |
| study inflammation | #160 |
| chemokines production | #161 |
| thirtysix eyes | #161 |
| muc16 | #161 |
| acid schiff | #161 |
| 28 female | #161 |
| elevation study | #161 |
| mucin 5ac | #161 |
| 326 years | #162 |
| surgery topical | #162 |
| distance visual acuity | #162 |
| male meibomian | #162 |
| bromobenzenes | #162 |
| twentynine eyes | #163 |
| olopatadine | #163 |
| efficacy tacrolimus | #163 |
| il1beta il2 | #163 |
| oxidative stress status | #163 |
| visit 7 | #163 |
| studied 21 | #163 |
| prevalence ocular | #163 |
| spt positive | #164 |
| patients topical | #164 |
| steroid anti | #164 |
| 30ng | #164 |
| 002 treatment | #164 |
| soft contact | #164 |
| purpose reported | #164 |
| production prostaglandin | #165 |
| biological dressings | #165 |
| cytometry hla | #166 |
| fluorescein humans | #166 |
| pgd2 induced | #166 |
| tacrolimus ointment | #167 |
| cytokines allergic | #167 |
| eosinophils higher | #167 |
| males 5 | #168 |
| ulcers erosions | #168 |
| steroidal blotting | #169 |
| eotaxin chemokine | #169 |
| patients postsurgical | #169 |
| 12 males | #169 |
| local allergic | #169 |
| seldi | #169 |
| treating refractory | #169 |
| studies tacrolimus | #169 |
| expression chemokines | #170 |
| status inflammation | #171 |
| management enzyme | #171 |
| conjunctiva conjunctival | #171 |
| subbasal nerve | #172 |
| palisades | #173 |
| fibroblasts fibroblast | #173 |
| subjective symptoms | #174 |
| vivo confocal | #174 |
| distance acuity | #174 |
| slit lamp | #174 |
| status oxidative | #174 |
| pcr flow | #174 |
| standard conventional | #174 |
| 34 eyes | #175 |
| postkeratoplasty | #175 |
| homologous molecule | #176 |
| evaluated symptoms | #176 |
| treatment corneal | #177 |
| subbasal | #177 |
| dust extract | #177 |
| aldehydes biomarkers | #177 |
| study longterm outcomes | #177 |
| reduction intraocular pressure | #178 |
| endophthalmitis female | #178 |
| acrysof | #178 |
| tryptase | #178 |
| strabismus adolescent | #178 |
| mild 2 | #178 |
| risk ocular | #179 |
| chemokine genes | #179 |
| myopic regression | #180 |
| compared eye | #180 |
| japan young adult | #180 |
| 4 female | #180 |
| migration eosinophils | #180 |
| ceramides child | #180 |
| dyes follow | #180 |
| lipid study | #181 |
| cutometer | #181 |
| normal control patients | #181 |
| lipoproteins micafungin | #183 |
| blepharitis | #183 |
| serum il4 | #183 |
| male radioallergosorbent | #184 |
| mucin4 mucins | #185 |
| human lymphocyte antigen | #185 |
| igg virus | #185 |
| examined parameters | #186 |
| therapy corneal | #186 |
| nerve prospective | #186 |
| suspensions administration | #187 |
| corneal fibroblasts | #187 |
| par2 mrna | #187 |
| drug fibroblasts humans | #187 |
| atopic eosinophils | #187 |
| efficacy topical | #187 |
| corneal sensitivity | #188 |
| eye symptoms | #188 |
| 19 eyes | #188 |
| il13 increased | #188 |
| production stromal | #189 |
| allergic cross | #189 |
| sensitivity regulation | #189 |
| seconds patients | #189 |
| levels 33 | #190 |
| infiltrating eosinophils | #191 |
| effects diesel | #191 |
| tear break | #191 |
| assisted infrared | #191 |
| improvement subjective | #192 |
| controls vivo | #193 |
| therapeutic study | #193 |
| allergic rhinoconjunctivitis | #193 |
| 26 eyes | #194 |
| fibroblasts inhibited | #195 |
| reactivation epstein | #195 |
| expression rantes | #195 |
| female histamine | #196 |
| rigid gas | #196 |
| interleukin4 production | #197 |
| eyes 21 | #197 |
| treatment topical | #197 |
| methods primary | #197 |
| tear film stability | #197 |
| 80 allergens | #197 |
| 28 eyes | #198 |
| combination topical | #198 |
| elisa performed | #198 |
| tears time | #198 |
| pollen prospective | #199 |
| effects topical | #199 |
| mcp1 ip10 | #201 |
| pollen allergic | #201 |
| perennial allergic | #201 |
| photorefractive keratectomy | #201 |
| preservative free | #201 |
| rsv infected | #202 |
| unit density | #202 |
| hypersensitivity interleukin13 | #202 |
| receptor homologous | #202 |
| eosinophils neutrophils | #203 |
| vcam1 icam1 | #204 |
| grade scale | #204 |
| differences iop | #204 |
| pge2 human | #204 |
| ova alum | #204 |
| inflammatory allergic | #205 |
| eyes 005 | #205 |
| disease dry | #206 |
| time tbut | #206 |
| disease acd | #206 |
| minutes 8 | #206 |
| eyes cataract | #206 |
| ecp levels | #207 |
| glands middle | #207 |
| pressure lens | #207 |
| crth2 | #207 |
| count cornea | #207 |
| formation giant | #207 |
| fluorescein fluorescent | #208 |
| size contact | #208 |
| tears aged | #208 |
| mammalian milk | #208 |
| analysis pm25 | #209 |
| uncorrected corrected | #209 |
| treatment allergic | #210 |
| human allergic | #210 |
| month reduction | #210 |
| refractory conventional | #211 |
| oct diagnosis | #211 |
| antiallergic drug | #211 |
| tacrolimus combination | #212 |
| iol patients | #212 |
| combination tests | #212 |
| inflammation injection | #212 |
| conjunctiva eye | #213 |
| treated refractory | #213 |
| chamber anti | #213 |
| muc5ac | #214 |
| steroids treatment | #214 |
| alpha il4 | #215 |
| ige higher | #216 |
| conjunctival goblet | #217 |
| allergic agents | #217 |
| worse eyes | #218 |
| lens purpose | #218 |
| expressions higher | #219 |
| nuclear cataract | #219 |
| metabolism lysine | #220 |
| tranilast | #220 |
| conjunctival biopsy | #220 |
| august october | #220 |
| conjunctivitis acute | #221 |
| findings inflammation | #221 |
| samples correlated | #222 |
| diseases dry | #222 |
| cells crth2 | #222 |
| twentyfour eyes | #222 |
| combined therapy | #222 |
| level ambient | #222 |
| 26 control subjects | #224 |
| iop corneal | #224 |
| sensitivity measurements | #224 |
| symptoms short | #224 |
| allergic drug | #225 |
| patients eye | #226 |
| 17 eyes | #227 |
| eyes adult | #228 |
| treatment 3 months | #228 |
| corneal clarity | #228 |
| followup cases | #229 |
| itching | #229 |
| corrected distance | #230 |
| treatment superior | #230 |
| eye signs | #230 |
| activity eosinophils | #231 |
| exhaust particles | #231 |
| 30 eyes | #231 |
| alpha defensin | #232 |
| scleral flap | #232 |
| examined level | #232 |
| events initiation | #232 |
| proteinchip | #233 |
| anti allergic | #233 |
| cyclosporine treatment | #233 |
| 791 patients | #233 |
| dye staining | #233 |
| concomitantly administered | #233 |
| 644 years | #234 |
| examined production | #235 |
| cultured eosinophils | #235 |
| quantitatively evaluate | #236 |
| corneal disease | #236 |
| specimens patients | #236 |
| term topical | #237 |
| gamma transcripts | #237 |
| topical steroid | #238 |
| tool quantitative | #240 |
| studied subjects | #240 |
| proliferative lesions | #240 |
| diagnostic abilities | #240 |
| eyes ocular | #241 |
| bf patients | #241 |
| cromolyn sodium | #242 |
| cell chemotactic | #242 |
| surface lipid | #242 |
| common ocular | #245 |
| performed higher | #245 |
| specular microscopy | #246 |
| eye drops | #247 |
| equivalent 2 | #247 |
| subjects males | #247 |
| specificity cutoff | #248 |
| chemosis | #248 |
| failure visual | #250 |
| response prostaglandin | #251 |
| labeling intercellular | #251 |
| seasonal allergic | #252 |
| subjective objective | #252 |
| males 13 | #252 |
| leukocyte child | #252 |
| syndrome tears | #252 |
| topical oral | #253 |
| levels tacrolimus | #253 |
| corneal female | #255 |
| improved vision | #255 |
| muc | #255 |
| rantes expression | #256 |
| dexamethasone inhibition | #256 |
| stability positive | #256 |
| disease corneal | #257 |
| treating severe | #257 |
| eosinophil chemotaxis | #258 |
| tear | #259 |
| questionnaire objective | #259 |
| eosinophil infiltration | #260 |
| role histamine | #260 |
| eyes control | #260 |
| additional medications | #260 |
| month treatment | #260 |
| expression rsv | #261 |
| human transcription | #261 |
| smaller normal | #262 |
| h1 antagonist | #262 |
| aged mucin | #264 |
| severity adverse | #264 |
| 1 month treatment | #264 |
| immunohistochemistry increased | #264 |
| steroid induced | #265 |
| keratoplasty pkp | #265 |
| controls p0001 | #266 |
| eyelid diseases | #266 |
| data weekly | #267 |
| signs blood | #267 |
| patients sjögren syndrome | #268 |
| microscopy negative | #268 |
| treatment atopic | #268 |
| respiratory syncytial virus | #268 |
| studied production | #268 |
| sodium drug | #269 |
| computer terminals | #270 |
| aged aldehyde | #270 |
| h1 histamine | #270 |
| dry eye symptoms | #271 |
| prevalence allergic | #272 |
| improved visual acuity | #273 |
| aldose reductase inhibitor | #273 |
| 13 males | #273 |
| combination eosinophils | #274 |
| epithelium endothelium | #274 |
| concentration quantitative | #274 |
| studies stevens | #274 |
| meibomian gland dysfunction | #275 |
| meibomian gland | #277 |
| tear breakup time | #277 |
| patients sjögren | #277 |
| tbut | #278 |
| grading score | #278 |
| individuals pcr | #278 |
| 0001 diagnosis | #279 |
| 13 females | #279 |
| bloodaqueous barrier | #279 |
| eyes 14 | #279 |
| interleukin il4 | #280 |
| multifunctional glycoprotein | #280 |
| 10 seconds | #281 |
| required provide | #281 |
| cautery | #282 |
| disease purpose | #282 |
| expressed th2 | #282 |
| gland dysfunction | #284 |
| ige positive | #284 |
| amniotic membrane | #285 |
| contralateral eye | #285 |
| seasons adolescent | #286 |
| atopic | #286 |
| th2 cytokines | #287 |
| cases refractory | #288 |
| layer adult | #288 |
| study tacrolimus | #289 |
| adult alkylating | #289 |
| entericcoated | #291 |
| eyedrops | #291 |
| water child | #292 |
| iop glaucoma | #293 |
| exponential equation | #294 |
| treatment 01 | #294 |
| new antifungal | #294 |
| single therapy | #295 |
| levels ige | #295 |
| serum periostin | #295 |
| surgery statistically | #297 |
| hyperemia | #297 |
| seventy eyes | #299 |
| ccl11 chemokine | #300 |
| rose bengal | #300 |
| severity diagnosis | #300 |
| pkp | #301 |
| benzalkonium chloride | #301 |
| morphologic alterations | #302 |
| assessed based | #303 |
| cobblestone | #303 |
| moderate 3 | #303 |
| scanning laser | #304 |
| photophobia | #304 |
| operation patient | #305 |
| initiation treatment | #305 |
| scores worse | #305 |
| eczema severity | #306 |
| piperidines treatment | #306 |
| assessed 4 | #307 |
| membrane patch | #307 |
| gel application | #308 |
| 10 normal subjects | #309 |
| interleukin13 interleukin2 | #309 |
| evaluation groups | #309 |
| inflammatory cell | #310 |
| comfort level | #310 |
| compared simple | #310 |
| cytology specimens | #311 |
| slitlamp examination | #311 |
| 12 eyes | #311 |
| treatment seasonal | #311 |
| regard age | #311 |
| 7 eyes | #312 |
| molecules chronic | #313 |
| aged staining | #315 |
| eye adult | #315 |
| 19 normal | #316 |
| child corneal | #316 |
| cells cornea | #317 |
| interferometry light | #317 |
| analysis glaucoma | #318 |
| values lower | #319 |
| prospective singlearm study | #320 |
| dermatitis clinical | #320 |
| fluorophotometry | #320 |
| cells chemotaxis | #321 |
| il8 rantes | #321 |
| bilateral cataracts | #323 |
| ulcers | #323 |
| pollen allergen | #324 |
| agreement weighted | #324 |
| eyes 19 | #325 |
| 15 30 minutes | #325 |
| 095 ± | #326 |
| icam1 vcam1 expression | #326 |
| surgery diabetic | #327 |
| chemokine concentrations | #327 |
| transplantation corneal | #328 |
| icam1 antibody | #329 |
| expression goblet | #329 |
| insensible | #330 |
| treatment 2 weeks | #331 |
| pressure ocular | #331 |
| dry eye disease | #332 |
| receptors il2r | #332 |
| leukocyte coculture | #333 |
| values daily | #335 |
| eye treated | #335 |
| cornea diagnostic | #335 |
| proprietary | #336 |
| 27 eyes | #337 |
| male staphylococcal | #337 |
| corneal epithelial | #337 |
| daily wear | #339 |
| signs clinical | #339 |
| eyes 27 | #341 |
| levels epithelial | #341 |
| methods eyes | #342 |
| asthenopia | #343 |
| illness tacrolimus | #344 |
| limbus | #346 |
| measurements treatment | #347 |
| corneal infection | #347 |
| eyes 13 | #348 |
| expression eosinophils | #348 |
| induced elevation | #348 |
| test values | #350 |
| surgery eye | #350 |
| contrast visual | #352 |
| surface diseases | #352 |
| iop elevation | #353 |
| weekly average | #354 |
| expression allergic | #354 |
| incidence allergic | #355 |
| temperature infrared | #355 |
| choroidal detachment | #356 |
| examination serum | #356 |
| patients allergy | #357 |
| tear film | #357 |
| local cytokine | #358 |
| eyes 8 | #358 |
| months conventional | #359 |
| tacrolimus tumor | #359 |
| difference efficacy | #361 |
| subjects 13 | #361 |
| agents benzophenones | #362 |
| messenger blotting | #363 |
| aureus patients | #363 |
| injections lidocaine | #364 |
| plant pollen | #368 |
| function laser | #368 |
| treatment ocular | #368 |
| studies sclera | #368 |
| corneae male | #369 |
| postoperative adhesion | #370 |
| eyes 17 | #370 |
| mucin1 mucin2 | #370 |
| systemic control | #371 |
| cryptomeria japonica | #372 |
| inhibitors epithelium | #372 |
| sixteen eyes | #373 |
| periodic acid schiff | #374 |
| micafungin middle | #374 |
| improvement local | #375 |
| cornea female | #375 |
| assessment severe | #375 |
| extraction cell | #376 |
| retina tomograph | #376 |
| levels atopic | #377 |
| higher human | #377 |
| phacoemulsification prospective | #377 |
| 4 lower | #377 |
| 10 normal | #377 |
| count child | #378 |
| treatment eyes | #378 |
| tarsal | #378 |
| mitomycin | #380 |
| stimulation tnf | #380 |
| corneal inflammation | #381 |
| cornea eye | #381 |
| negative serum | #382 |
| pollinosis | #383 |
| inflammation epithelial | #383 |
| examinations including | #384 |
| gas permeable | #384 |
| vivo corneal | #385 |
| ocular diseases | #386 |
| corneal epithelial cells | #386 |
| surface alterations | #388 |
| limit assay | #388 |
| decrease inflammatory | #388 |
| surgery 13 | #388 |
| healing adult | #389 |
| cells vehicle | #389 |
| sde | #390 |
| severity incidence | #390 |
| patients proteins | #391 |
| antiallergic | #391 |
| breakup time | #393 |
| immunohistochemistry tests | #394 |
| 44 eyes | #395 |
| chronic ocular | #395 |
| applied 5 | #395 |
| opacity corneal | #396 |
| techniques interleukin4 | #396 |
| relative percentages | #396 |
| apparatus lacrimal | #397 |
| expression lower | #397 |
| increased understanding | #398 |
| pressure elevation | #399 |
| ocular surface disease | #399 |
| remission based | #400 |
| declaration helsinki | #400 |
| modified boyden | #401 |
| eyes severe | #401 |
| rays male | #402 |
| sedating humans | #403 |
| cells allergic | #404 |
| weather air | #404 |
| vogt | #404 |
| measurements oct | #404 |
| prospective controlled study | #405 |
| patients epithelial | #406 |
| reproducibility surface | #406 |
| improved diagnosis | #407 |
| serum total ige | #407 |
| 137 years | #407 |
| postoperative aged | #408 |
| activated fibroblasts | #409 |
| heidelberg retina tomograph | #410 |
| confocal | #412 |
| eyes 15 | #412 |
| specific total | #412 |
| acids fibroblasts | #412 |
| 3 months treatment | #413 |
| counts 1 | #413 |
| allergic reaction | #413 |
| keratocytes | #414 |
| postoperative inflammation | #416 |
| limbal | #416 |
| penetrating keratoplasty | #418 |
| central cornea | #418 |
| chemokine ccl11 | #419 |
| mucin4 | #419 |
| patients comfort | #419 |
| speed resolution | #419 |
| ophthalmologist | #420 |
| sjögren syndrome | #420 |
| lacrimal gland | #422 |
| 20 normal controls | #424 |
| clinical observation | #425 |
| 40 minutes | #425 |
| production 4 | #430 |
| trabeculectomy visual | #430 |
| staining score | #431 |
| rhinoconjunctivitis | #431 |
| 0 normal | #433 |
| subjects atopic | #434 |
| cedrus | #437 |
| performed immunohistochemistry | #437 |
| regulation eye | #438 |
| methods eye | #438 |
| 5 women | #438 |
| commercial tests | #439 |
| interleukin4 il4 | #440 |
| subjects studied | #440 |
| foldable | #440 |
| vmr | #441 |
| fluorescein dye | #441 |
| landolt | #441 |
| regulation chemokine | #441 |
| anti vcam1 | #442 |
| females normal | #442 |
| adult aldehydes | #442 |
| 17 males | #444 |
| male mucin1 | #444 |
| patients combined therapy | #445 |
| 39 consecutive patients | #447 |
| dogs dust | #448 |
| air pollution data | #448 |
| 30 serum | #450 |
| male 4 | #450 |
| eye eyes | #451 |
| wash | #452 |
| keratoplasty | #452 |
| ketotifen | #453 |
| antagonists sedating | #453 |
| versus vehicle | #453 |
| normal patients | #454 |
| vivo confocal microscopy | #454 |
| surface disorder | #454 |
| response allergens | #454 |
| production clearance | #455 |
| water evaporation | #455 |
| ophthalmic nerve | #455 |
| 8 genes | #455 |
| agonists pilocarpine | #456 |
| humans keratoplasty | #456 |
| ocular risk | #457 |
| normal controls patients | #457 |
| amnion cell | #457 |
| outpatient visits | #457 |
| checker | #459 |
| oct study | #460 |
| greatest improvements | #461 |
| distance visual | #461 |
| test evaluation | #462 |
| keratoplasty penetrating | #462 |
| hel | #466 |
| fibroblasts tgf | #467 |
| unpaired ttest | #467 |
| study pcr | #468 |
| examination diagnosis | #469 |
| background atopic | #469 |
| major sources | #470 |
| allergy adult | #473 |
| markers severity | #473 |
| metry | #475 |
| hladr expression | #476 |
| diagnosis rate | #476 |
| 13 mmhg | #478 |
| pollen seasons | #478 |
| fibroblasts primary | #478 |
| newly formed vessels | #480 |
| reduce clinical | #480 |
| height measurement | #480 |
| subjects eyes | #481 |
| examined prospective | #482 |
| interleukin 13 | #482 |
| crystalline lens implantation | #485 |
| 21 eyes | #488 |
| accommodating | #488 |
| induced 15 | #489 |
| myopia photorefractive | #490 |
| shortterm study | #490 |
| disodium cromoglycate | #493 |
| prolonged inflammation | #495 |
| ebv reactivation | #495 |
| acuity intraocular | #495 |
| corneal | #498 |
| months eyes | #498 |
| il2 tumor | #499 |
| exposure diesel | #499 |
| stain positive | #499 |
| silicone hydrogel | #500 |
| lens iol | #500 |
| infections viral | #501 |
| symptoms efficacy | #501 |
| studies status | #502 |
| pge2 cox2 | #502 |
| treatment eye | #502 |
| heidelberg retina | #503 |
| 42 eyes | #504 |
| 2 daily | #505 |
| eye position | #505 |
| inflammatory status | #506 |
| correlate severity | #506 |
| airborne particulate matter | #506 |
| penetrating male | #507 |
| induced ocular | #509 |
| aldose reductase | #509 |
| 1 mild | #511 |
| cats child | #512 |
| treatment visual | #514 |
| 45 subjects | #516 |
| topical | #516 |
| disposable equipment | #517 |
| inhibition production | #519 |
| observed baseline | #519 |
| male water | #519 |
| groups duration | #520 |
| lipopeptides lipoproteins | #520 |
| chemoattractant receptor | #522 |
| 01 | #522 |
| metaregression analysis | #523 |
| 10 normal volunteers | #524 |
| infection rsv | #524 |
| studies trabeculectomy | #525 |
| dinoprostone epithelial | #525 |
| trabeculectomy | #527 |
| studies cornea | #527 |
| giemsa staining | #528 |
| density basal | #528 |
| itchy | #531 |
| rhodanine | #531 |
| ocular symptoms | #535 |
| serum antigen | #535 |
| 44yearold | #536 |
| purpose case | #537 |
| total hydrocarbons | #538 |
| patients cataract | #538 |
| sac | #539 |
| dependent migration | #539 |
| capsular bag | #540 |
| placebo tablets | #540 |
| 80 anterior | #541 |
| visit 6 | #541 |
| cases flow | #542 |
| administration topical | #542 |
| 20 normal | #543 |
| infrared radiation | #543 |
| 6 male | #544 |
| ebv nuclear antigen | #546 |
| production cultured | #546 |
| time improved | #547 |
| pollution allergens | #549 |
| periodic acid | #549 |
| prospective comparative study | #550 |
| film layer | #550 |
| cryptomeria | #552 |
| il‐4 | #552 |
| disease complicated | #553 |
| effects cooling | #553 |
| engorgement | #554 |
| genechip | #555 |
| disease ded | #555 |
| fibroblasts response | #555 |
| setting department | #556 |
| noninfected cells | #557 |
| transplantation combined | #558 |
| density assessed | #558 |
| diesel exhaust particles | #559 |
| methods thirty | #559 |
| eyes iop | #560 |
| differentiation inflammatory | #560 |
| ocular infections | #560 |
| laser trabeculoplasty | #562 |
| eyes 24 | #562 |
| positive 30 | #563 |
| count corneal | #569 |
| 16 age | #569 |
| cultured corneal | #570 |
| levels il4 | #570 |
| meibomian | #572 |
| female humans specificity | #576 |
| allergen challenge | #577 |
| corneal diseases | #578 |
| 4 mrna | #580 |
| iop eyes | #580 |
| apparatus male | #582 |
| fibrosis fluorescent | #582 |
| lesions normal | #582 |
| tnfalpha stimulation | #584 |
| increase vegf | #584 |
| department ophthalmology | #584 |
| symptoms scores | #588 |
| corneal epithelium | #589 |
| patients csa | #589 |
| induced 4 | #589 |
| hladr antigen | #589 |
| intraocular male | #589 |
| female humans allergic | #589 |
| study lipid | #590 |
| diseases regulation | #591 |
| icam1 vcam1 | #592 |
| cytological techniques | #593 |
| observed real | #595 |
| findings evaluated | #597 |
| assay eye | #597 |
| epithelium corneal | #598 |
| cells chemokine | #599 |
| diesel exhaust | #602 |
| cornea epithelium | #603 |
| mrna tgf | #604 |
| thermometer | #605 |
| grading scale | #606 |
| inflammation status | #609 |
| topical adult | #609 |
| thermography | #611 |
| corneal nerves | #611 |
| eosinophils epithelial | #612 |
| fluorescent dyes humans | #613 |
| synergic | #614 |
| antagonists humans | #615 |
| patients complained | #615 |
| diagnosis type | #616 |
| cells oligopeptides | #616 |
| grades 0 | #617 |
| ocular allergy | #617 |
| flaps suture | #618 |
| subjects conclusion | #621 |
| il4 | #623 |
| glaucoma medications | #625 |
| lamp examination | #625 |
| years studied | #625 |
| ophthalmologists | #626 |
| occlusion treatment | #628 |
| micafungin | #635 |
| patients tacrolimus | #636 |
| burning sensation | #636 |
| corneal haze | #636 |
| redness | #636 |
| total immunoglobulin | #638 |
| based severity | #639 |
| eosinophils | #639 |
| contact lenses | #639 |
| 511 patients | #640 |
| male rhinitis | #640 |
| 11 eyes | #641 |
| development allergic | #641 |
| symptoms signs | #643 |
| performed modified | #643 |
| months 01 | #643 |
| observed follow | #644 |
| mellitus double | #645 |
| fibrosis actins | #645 |
| patients healthy volunteers | #650 |
| viscosupplements | #651 |
| 2 females | #651 |
| expression administration | #651 |
| analysis existence | #654 |
| eosinophils flow | #654 |
| diseases methods | #656 |
| lacrimal | #657 |
| comfortable | #657 |
| patients elisa | #660 |
| nerve density | #661 |
| 96well plate | #661 |
| chamber technique | #662 |
| lens wearers | #664 |
| treatment 0001 | #664 |
| acuity measured | #665 |
| molecule1 cell | #668 |
| 10 age | #669 |
| damage scores | #669 |
| viruses acute | #669 |
| cedar | #672 |
| stimulation rna | #672 |
| humans lacrimal | #673 |
| 11 males | #673 |
| scleritis | #677 |
| levels correlation | #678 |
| administration ophthalmic | #680 |
| adherence anti | #681 |
| test methods | #681 |
| antibody negative | #682 |
| chemokine gene | #683 |
| stainings | #684 |
| fibronectin cell | #684 |
| single visit | #685 |
| goblet | #686 |
| cells collected | #688 |
| differential diagnosis patients | #689 |
| visual acuity patients | #690 |
| cells eye | #694 |
| atopic female humans | #694 |
| 1 test | #695 |
| inhibition expression | #697 |
| early antigen | #697 |
| objective assessments | #700 |
| cromolyn | #700 |
| levels detection | #700 |
| intraocular inflammation | #703 |
| eyelid | #704 |
| labeling surface | #705 |
| antineoplastic child | #707 |
| participants eyes | #709 |
| pain baseline | #711 |
| allergens child | #712 |
| fibroblasts flow | #715 |
| 1 month | #715 |
| major characteristic | #717 |
| 5 eyes | #718 |
| key cells | #718 |
| dibenzazepines | #719 |
| preventing recurrence | #721 |
| production vascular | #722 |
| 088 ± | #724 |
| 32 eyes | #724 |
| promising treatment strategy | #725 |
| squamous metaplasia | #729 |
| aged ophthalmology | #730 |
| 11 male | #730 |
| followup treatment | #730 |
| cytology patients | #731 |
| eyes underwent | #733 |
| pollution data | #735 |
| suppressive effects | #736 |
| symptoms 5 | #737 |
| reductase inhibitor | #737 |
| intraocular lens | #740 |
| keratectomy | #741 |
| density compared | #741 |
| expression real | #744 |
| unpaired test | #746 |
| definition classification | #746 |
| blood eosinophils | #746 |
| inflammation lipid | #748 |
| purpose hypothesis | #749 |
| cornea corneal | #751 |
| daily weather | #751 |
| interleukin13 male | #752 |
| fibroblasts cultured | #754 |
| eyes 6 | #758 |
| iol implantation | #759 |
| follow cases | #759 |
| allergens anti | #762 |
| trabeculectomy treatment | #763 |
| topical aged | #763 |
| intraocular lens implantation | #763 |
| 148 years | #764 |
| drugs primary | #765 |
| aged chemokine | #766 |
| oligopeptides rna | #769 |
| pathogenesis severe | #769 |
| measurements improved | #772 |
| pge2 production | #775 |
| eotaxin | #776 |
| cells adolescent | #782 |
| levels prostaglandin | #783 |
| role allergic | #783 |
| limbus corneae | #784 |
| fluorescein fluoresceins | #784 |
| purpose analyze | #785 |
| treatment 1 | #785 |
| blinking | #785 |
| elevated levels | #789 |
| allergic disease | #790 |
| eyes normal | #792 |
| lenses intraocular | #792 |
| increased epithelial | #793 |
| techniques laminin | #793 |
| tacrolimus | #793 |
| 4 hne | #794 |
| ocular inflammation | #794 |
| months visual | #798 |
| treatment p0001 | #800 |
| positive linear | #801 |
| report efficacy | #801 |
| radioallergosorbent | #802 |
| excimer male | #804 |
| cells western | #806 |
| receptors ccr3 | #813 |
| mucin | #813 |
| 21 individuals | #814 |
| brush | #816 |
| acuity adolescent | #817 |
| biomicroscopy | #819 |
| concentration dose | #820 |
| aged cell | #820 |
| interleukin4 | #821 |
| cells eosinophils | #821 |
| phenotype practice | #822 |
| temperature case | #825 |
| year adolescent | #831 |
| preoperative level | #834 |
| lymphocytes compared | #834 |
| surgical outcome | #835 |
| cases follow | #835 |
| pachymetry | #840 |
| individuals patients | #841 |
| patients operation | #841 |
| implantation intraocular | #842 |
| ocular adolescent | #843 |
| symptoms improved | #843 |
| elevated iop | #845 |
| new surgical technique | #845 |
| exhaust | #848 |
| 2 weeks treatment | #848 |
| levels air | #848 |
| loss insensible | #851 |
| fluorescein | #853 |
| purpose prospectively | #855 |
| cell area | #855 |
| 10 eyes | #858 |
| methane hydrocarbons | #860 |
| myopic eyes | #861 |
| inhibitors diclofenac | #861 |
| histamine h1 | #865 |
| thiazolidines | #865 |
| thirteen cases | #866 |
| patients ocular | #867 |
| test kits | #868 |
| serum antibody titers | #872 |
| patients eyes | #874 |
| 01 compared | #874 |
| dry eyes | #876 |
| mitomycinc | #878 |
| syndrome sjs | #879 |
| evaluation early | #880 |
| benzamidine | #880 |
| h1 antagonists | #880 |
| patient comfort | #881 |
| assessing efficacy | #882 |
| cells contributes | #882 |
| diseases background | #883 |
| study eye | #886 |
| patients condition | #887 |
| bleb | #887 |
| specular | #890 |
| respiratory syncytial | #894 |
| 114 years | #894 |
| age eye | #895 |
| noncomparative | #897 |
| pain inflammation | #901 |
| ocular | #902 |
| levels pm25 | #903 |
| 20 eyes | #904 |
| decreased baseline | #905 |
| benzophenones | #905 |
| circulating autoantibodies | #907 |
| clinical signs | #910 |
| lacrimal duct | #911 |
| examined pcr | #911 |
| aureus young | #912 |
| gauze | #917 |
| corneae | #919 |
| sjögren | #920 |
| immunoglobulin immunosuppressive | #921 |
| 10 females | #925 |
| 8 males | #928 |
| treatment symptoms | #928 |
| immunoregulatory effects | #929 |
| epithelial lesions | #929 |
| histopathologic analysis | #930 |
| disease efficacy | #932 |
| normal controls | #933 |
| ophthalmologic surgical | #933 |
| beta1 tumor | #937 |
| epithelialization | #937 |
| iop measured | #939 |
| treatment severe | #940 |
| cytokines epithelial | #941 |
| symptoms evaluated | #941 |
| normal 1 | #943 |
| factor production | #946 |
| humans muscarinic | #946 |
| wheal | #947 |
| mgd | #949 |
| radioallergosorbent test | #949 |
| humans lenses | #950 |
| seasons young | #950 |
| ulcer humans | #952 |
| sensitivity values | #953 |
| 2 moderate | #957 |
| scanning confocal | #957 |
| aldose | #959 |
| 3 eyes | #959 |
| singleagent therapy | #959 |
| endpoint baseline | #960 |
| intracellular infection | #961 |
| sedating | #961 |
| expression 8 | #962 |
| dust mites | #963 |
| observed 3 | #965 |
| eyes 12 | #966 |
| ecp | #967 |
| total score | #968 |
| expression chemokine | #969 |
| positively stained | #971 |
| basal epithelial | #973 |
| term therapeutic | #973 |
| mcp1 gene | #980 |
| day month | #981 |
| 6 males | #983 |
| detected patients | #985 |
| ointment | #989 |
| 4 regulation | #990 |
| primary cultured | #992 |
| carried patients | #993 |
| tenon | #994 |
| observed conclusions | #994 |
| technique 2 | #998 |
| adult cornea | #1001 |
| observed vivo | #1002 |
| methods sixteen | #1002 |
| serum ige | #1005 |
| pediatric subjects | #1008 |
| accommodation ocular | #1009 |
| boyden | #1011 |
| time year | #1012 |
| eye infections | #1012 |
| piperidines pyridines | #1013 |
| allergic diseases | #1014 |
| 1 2 weeks | #1017 |
| blink | #1017 |
| normal volunteers | #1019 |
| impression | #1019 |
| improved 1 | #1020 |
| cells positively | #1021 |
| ω3 fatty acids | #1024 |
| model allergic | #1028 |
| studied prospectively | #1029 |
| induced chemotaxis | #1031 |
| diopter | #1032 |
| improved 3 | #1033 |
| 2 eyes | #1036 |
| patching | #1040 |
| webbased questionnaire | #1040 |
| 045 ± | #1040 |
| chemotaxis | #1042 |
| values analysis | #1043 |
| cells fibroblasts | #1044 |
| lysine 4 | #1044 |
| concomitantly | #1045 |
| treatment skin | #1045 |
| xerophthalmia | #1046 |
| recurrence 6 | #1050 |
| indirect humans | #1050 |
| allergen extracts | #1053 |
| symptoms score | #1054 |
| johnson syndrome | #1057 |
| eyelids | #1059 |
| study therapeutic | #1060 |
| allograft transplantation | #1062 |
| guidelines clinical | #1064 |
| giemsa | #1065 |
| disposable | #1067 |
| pollution risk | #1067 |
| staphylococcal enterotoxin | #1067 |
| noninfectious | #1070 |
| acuity patients | #1071 |
| goblet cell | #1071 |
| immunocytochemical study | #1073 |
| months corrected | #1075 |
| effective treating | #1075 |
| eyes received | #1076 |
| efficacy treatment | #1077 |
| benzamidines | #1079 |
| techniques ophthalmological | #1080 |
| ade | #1080 |
| syncytial virus | #1080 |
| allergic inflammatory | #1082 |
| expression icam1 | #1082 |
| sex matched | #1088 |
| cyclosporine patients | #1091 |
| ige anti | #1098 |
| corrected visual acuity | #1099 |
| diseases objective | #1104 |
| assessed vivo | #1104 |
| endothelium corneal | #1107 |
| 10 males | #1109 |
| meibomian glands | #1110 |
| rose | #1116 |
| lens capsule | #1116 |
| 30 patients | #1118 |
| drops | #1121 |
| keratopathy | #1121 |
| 92 years | #1122 |
| popularization | #1122 |
| periostin | #1125 |
| epithelium female | #1132 |
| clinical findings | #1133 |
| cultures human | #1133 |
| assay fibroblasts | #1133 |
| treatment objective | #1133 |
| anti icam1 | #1134 |
| evaluate therapeutic | #1136 |
| controls examined | #1137 |
| healthy eyes | #1140 |
| visual acuities | #1140 |
| prospective controlled | #1141 |
| small incision | #1143 |
| p0035 | #1146 |
| 4 daily | #1146 |
| minimum angle | #1149 |
| aphakic | #1150 |
| aged phacoemulsification | #1153 |
| cyclosporine humans | #1154 |
| interventional case | #1157 |
| airborne particulate | #1165 |
| sjögrens syndrome | #1171 |
| purpose evaluate | #1171 |
| glands sjogren | #1173 |
| cornea | #1173 |
| immune mechanisms | #1189 |
| fibronectins fibrosis | #1189 |
| ophthalmological female | #1189 |
| adult dermatitis | #1191 |
| levels chemokines | #1191 |
| spatial temporal resolution | #1193 |
| cytokine mrna | #1195 |
| refractory standard | #1207 |
| ded | #1209 |
| 84 ± | #1210 |
| concentrations alpha | #1210 |
| 18 females | #1211 |
| boyden chamber | #1212 |
| lasers excimer | #1215 |
| bengal | #1217 |
| scl | #1219 |
| stevens johnson | #1220 |
| par2 | #1222 |
| 025 | #1223 |
| mmc | #1230 |
| microscopy confocal | #1231 |
| allergic inflammation | #1233 |
| instilled | #1235 |
| correlation clinical | #1240 |
| wearers | #1241 |
| eyes treated | #1242 |
| muc5ac expression | #1249 |
| supply adult | #1254 |
| molecule expressed | #1265 |
| messenger reverse | #1266 |
| levels pge2 | #1270 |
| tomograph | #1271 |
| 4 normal | #1274 |
| period clinical | #1275 |
| anesthesia local | #1278 |
| study eyes | #1286 |
| aged substance | #1286 |
| 169 ± | #1287 |
| lacrimal apparatus | #1288 |
| dermatitis atopic | #1289 |
| phacoemulsification | #1290 |
| iol | #1294 |
| cac | #1300 |
| adult antibiotics | #1301 |
| controls 005 | #1302 |
| dryness | #1303 |
| photorefractive | #1304 |
| spring autumn | #1307 |
| intraocular lenses | #1308 |
| japanese cedar | #1310 |
| thermometry | #1311 |
| allergic | #1314 |
| chemokines chemotaxis | #1316 |
| higher severe | #1316 |
| corneal humans | #1317 |
| presence increased | #1318 |
| expressed secreted | #1321 |
| child chromatography | #1321 |
| ccl11 | #1322 |
| 830 | #1322 |
| membrane increased | #1331 |
| treatment improvements | #1334 |
| prostaglandin production | #1335 |
| light lipid | #1337 |
| ccr3 receptors | #1340 |
| fivepoint scale | #1341 |
| operation patients | #1343 |
| ped | #1348 |
| treatment 14 | #1353 |
| antigen child | #1360 |
| benzalkonium | #1365 |
| responses peripheral | #1371 |
| cytokines dinoprostone | #1374 |
| atopic diseases | #1377 |
| 00001 lower | #1383 |
| timeseries analysis | #1384 |
| ointments | #1396 |
| 18 eyes | #1399 |
| female glucocorticoids | #1399 |
| respiratory pathogen | #1404 |
| epithelial barrier function | #1407 |
| proteaseactivated receptor | #1413 |
| diseases diagnosis | #1413 |
| adult allergens | #1414 |
| normal adults | #1416 |
| 005 1 | #1419 |
| 1 week | #1425 |
| prospective comparative | #1428 |
| higher contrast | #1431 |
| patients cgvhd | #1432 |
| rast | #1434 |
| factors seasons | #1439 |
| haze | #1444 |
| corneal neovascularization | #1444 |
| temperature cell | #1445 |
| goblet cells | #1451 |
| reduced 1 | #1451 |
| macular oedema | #1453 |
| histocytological | #1458 |
| corneal opacity | #1465 |
| lens implantation | #1469 |
| complained | #1470 |
| production il4 | #1481 |
| outcome administration | #1488 |
| corneal edema | #1489 |
| data daily | #1497 |
| 2 minutes | #1498 |
| western cells | #1499 |
| detected frequently | #1499 |
| male metaplasia | #1500 |
| studies suture | #1502 |
| bulbar | #1502 |
| pgd2 | #1505 |
| human corneal | #1507 |
| ophthalmological | #1510 |
| female fluorescein | #1514 |
| staining | #1514 |
| 40 mmhg | #1522 |
| studies glaucoma | #1524 |
| total scores | #1526 |
| eosinophils female | #1527 |
| acuity adult | #1530 |
| inhibitors child | #1533 |
| cells density | #1537 |
| 7 females | #1541 |
| production primary | #1542 |
| cytometric analysis | #1544 |
| dioxide particulate | #1548 |
| virus rsv | #1553 |
| pollen rhinitis | #1559 |
| decreased treatment | #1560 |
| steroidal cell | #1566 |
| aged allergens | #1571 |
| fibronectin laminin | #1573 |
| cells 001 | #1575 |
| 15 females | #1580 |
| purpose investigate | #1581 |
| fibroblasts | #1583 |
| effective long | #1589 |
| assessed quantitative | #1591 |
| aldehyde reductase | #1597 |
| ortho aminobenzoates | #1602 |
| preservative | #1602 |
| cells 0001 | #1603 |
| humans intraocular | #1624 |
| vdt | #1624 |
| incidence adverse events | #1625 |
| weeks administration | #1629 |
| eye | #1630 |
| cyclosporine female | #1637 |
| epstein‐barr virus | #1638 |
| epsteinbarr virus ebv | #1641 |
| mitomycin mmc | #1643 |
| preschool dermatitis | #1644 |
| capsule crystalline | #1654 |
| subjects examined | #1658 |
| prevalence severe | #1662 |
| syncytial | #1663 |
| 10 healthy controls | #1663 |
| reaction young | #1665 |
| damage patients | #1666 |
| function small | #1670 |
| infections fungal | #1673 |
| higher normal | #1674 |
| 2 cytokine | #1685 |
| pm25 levels | #1686 |
| dose equivalent | #1687 |
| confocal middle | #1698 |
| 7 males | #1711 |
| disease defined | #1713 |
| outcome visual | #1713 |
| subjects adolescent | #1716 |
| whitney test | #1721 |
| 744 | #1725 |
| topical application | #1735 |
| central corneal | #1741 |
| cytology | #1741 |
| treatment short | #1742 |
| severity treatment | #1754 |
| years 19 | #1754 |
| antigen anti | #1756 |
| iols | #1760 |
| rsv infection | #1761 |
| eightysix patients | #1764 |
| oral steroids | #1775 |
| inflammation assessed | #1779 |
| enterotoxins female | #1789 |
| alpha sma | #1798 |
| mild cases | #1802 |
| 10 healthy | #1811 |
| endophthalmitis eye | #1815 |
| punctate | #1817 |
| antifungal treatment | #1821 |
| receptor par2 | #1823 |
| japan methods | #1823 |
| regulated activation | #1825 |
| sjs | #1827 |
| 15 minutes | #1828 |
| eosinophil | #1828 |
| child dermatitis | #1832 |
| epithelial damage | #1835 |
| mediator release | #1835 |
| factor tnfalpha | #1836 |
| fibroblasts normal | #1837 |
| corneal transplantation | #1838 |
| degrees 4 | #1839 |
| eye examination | #1840 |
| prostaglandin receptors | #1841 |
| inflammation injections | #1842 |
| month 3 | #1846 |
| effects aged | #1848 |
| receptors prostaglandin | #1853 |
| ulcer female | #1857 |
| 005 differences | #1858 |
| comparative evaluation | #1860 |
| shield | #1860 |
| ari | #1862 |
| tnfalpha production | #1862 |
| humans immunosuppressive | #1874 |
| surgery purpose | #1890 |
| aphakia | #1893 |
| cataract surgery | #1893 |
| ige production | #1900 |
| cells epithelial | #1909 |
| sterilized | #1912 |
| interleukin 4 | #1920 |
| ihc staining | #1923 |
| mast cell degranulation | #1929 |
| contact female | #1935 |
| contribute pathogenesis | #1942 |
| 013 ± | #1943 |
| protein female | #1946 |
| severe persistent | #1946 |
| patients exhibited | #1947 |
| score clinical | #1961 |
| vcam1 expression | #1962 |
| 9 males | #1970 |
| 5 minutes | #1970 |
| 4 males | #1971 |
| comfort | #1972 |
| device treatment | #1972 |
| corrected visual | #1974 |
| gpc | #1974 |
| month 1 | #1975 |
| intraocular | #1977 |
| nonuse | #1979 |
| eyes | #1980 |
| controls p005 | #1984 |
| females age | #1990 |
| studies cell | #1992 |
| irritation | #1994 |
| bak | #1999 |
| reaction serine | #2013 |
| diseases diagnostic | #2014 |
| erosions | #2016 |
| tacrolimus adult | #2023 |
| agents male | #2023 |
| surgery 1 | #2025 |
| ccl5 chemokines | #2026 |
| chemotaxis leukocyte | #2031 |
| increased vegf | #2036 |
| treated eyes | #2038 |
| coherence treatment | #2038 |
| based incidence | #2048 |
| eye female | #2049 |
| corneal topography | #2066 |
| ambient air pollution | #2067 |
| versus normal | #2067 |
| allergens animals | #2067 |
| pollen | #2068 |
| dexamethasone enzyme | #2073 |
| herpetic | #2075 |
| temperature measured | #2078 |
| cytokines enzyme | #2084 |
| ophthalmologic | #2091 |
| cytokines dose | #2093 |
| therapeutic effects | #2106 |
| aged antifungal | #2107 |
| activation normal | #2108 |
| clinical examinations | #2112 |
| cultured chemokine | #2118 |
| average concentrations | #2119 |
| acd | #2127 |
| reaction statistics | #2128 |
| human α | #2132 |
| docosahexaenoic acid | #2137 |
| endopeptidases serine | #2137 |
| mucin2 | #2140 |
| antibody positive | #2142 |
| vegf production | #2143 |
| incidence adverse | #2148 |
| scored | #2157 |
| controls 0001 | #2158 |
| expression patient | #2160 |
| umin | #2163 |
| production inhibited | #2164 |
| curve reproducibility | #2164 |
| virus human | #2170 |
| study flow | #2171 |
| density lower | #2174 |
| pressure iop | #2177 |
| sensation | #2181 |
| dyes humans | #2183 |
| adult administration | #2184 |
| regulation adolescent | #2185 |
| eyes patients | #2186 |
| eye disease | #2190 |
| child computer | #2191 |
| diseases female | #2192 |
| aged mitomycin | #2192 |
| duct obstruction | #2202 |
| pseudophakic | #2208 |
| ulcer patients | #2219 |
| cases severe | #2231 |
| greater concentrations | #2232 |
| 1 3 months | #2234 |
| immunoglobulin male | #2235 |
| upper lower | #2236 |
| matter pm25 | #2243 |
| vital | #2246 |
| rater agreement | #2246 |
| scores correlated | #2247 |
| pollens | #2247 |
| allergic seasonal | #2250 |
| groups difference | #2250 |
| tryptases | #2264 |
| compared vehicle | #2265 |
| individuals adolescent | #2270 |
| myopic | #2271 |
| slit | #2275 |
| il4 il13 | #2279 |
| exposure particulate | #2280 |
| uncorrected | #2284 |
| studies stem | #2285 |
| 6 months | #2290 |
| diseases enzyme | #2294 |
| cooling | #2297 |
| female gels | #2302 |
| humans hypersensitivity | #2311 |
| clinical appearance | #2312 |
| topical treatment | #2312 |
| rsv | #2316 |
| performed treatment | #2323 |
| animal study | #2332 |
| hours dose | #2336 |
| il4 production | #2339 |
| culture supernatants | #2343 |
| weeks 1 | #2344 |
| mann whitney | #2351 |
| ca125 antigen | #2354 |
| method assessing | #2371 |
| syncytial viruses | #2377 |
| skin adolescent | #2378 |
| treatment 2 | #2392 |
| immunosuppressive agents | #2409 |
| relieving | #2410 |
| months initiation | #2412 |
| ophthalmology | #2415 |
| aged nitrogen | #2415 |
| child enzyme | #2420 |
| stevens | #2422 |
| effective patients | #2424 |
| intraocular pressure | #2425 |
| prostaglandin | #2433 |
| interleukin2 receptors | #2456 |
| transcription levels | #2459 |
| sclera | #2464 |
| glaucoma humans | #2492 |
| ige antibody | #2493 |
| enteric coated | #2498 |
| fungal female | #2498 |
| diseases adolescent | #2503 |
| scores clinical | #2510 |
| obstruction male | #2513 |
| histamine | #2514 |
| h1 receptor | #2516 |
| histamine humans | #2533 |
| humans hyperemia | #2535 |
| levels alpha | #2543 |
| ebv | #2546 |
| patients symptoms | #2550 |
| cell expressed | #2557 |
| correlated severity | #2565 |
| oct | #2571 |
| methods clinical | #2571 |
| flare | #2573 |
| male polymerase | #2573 |
| controls serum | #2578 |
| penetrating | #2579 |
| mannwhitney | #2580 |
| vcam1 | #2583 |
| tonometry ocular | #2587 |
| aged myopia | #2593 |
| excimer laser | #2597 |
| methods subjects | #2602 |
| fibroblasts humans | #2610 |
| subjects 12 | #2614 |
| complications adolescent | #2619 |
| baseline treatment | #2620 |
| contact lens | #2624 |
| eosinophilia female | #2629 |
| postsurgical | #2629 |
| 6 months treatment | #2638 |
| lamp | #2646 |
| cyclosporine drug | #2647 |
| cyclosporine csa | #2653 |
| alpha adolescent | #2655 |
| 412 | #2656 |
| administered day | #2664 |
| rantes | #2665 |
| mucins | #2672 |
| cataract extraction | #2683 |
| symptom score | #2687 |
| infections respiratory | #2694 |
| groups differences | #2695 |
| tearing | #2698 |
| bf | #2698 |
| chemokine ccl5 | #2712 |
| studies glucocorticoids | #2717 |
| control eyes | #2721 |
| muc1 | #2726 |
| fibroblasts gene | #2731 |
| alpha vascular | #2735 |
| chemokine production | #2739 |
| hne | #2743 |
| factors chemotaxis | #2746 |
| laser scanning | #2747 |
| tomography oct | #2754 |
| immunocytochemical staining | #2759 |
| betamethasone | #2761 |
| matched normal | #2772 |
| total ige | #2772 |
| atopic female | #2773 |
| chronic graft | #2786 |
| humans immunoenzyme | #2792 |
| symptomatic improvement | #2794 |
| prevention adolescent | #2797 |
| male adolescent | #2813 |
| iop | #2817 |
| scores lower | #2818 |
| whitney | #2819 |
| atopic dermatitis | #2821 |
| higher cases | #2821 |
| dry | #2840 |
| groups normal | #2842 |
| analog scale | #2845 |
| aminobenzoates | #2846 |
| months surgery | #2850 |
| crystalline lens | #2855 |
| treatment 4 | #2868 |
| fibroblasts fibronectins | #2889 |
| qol scores | #2892 |
| syndrome patients | #2902 |
| evaporation rate | #2903 |
| mannwhitney test | #2905 |
| anterior chamber | #2907 |
| test performed | #2907 |
| il1beta | #2910 |
| tests diagnosis | #2922 |
| postoperative follow | #2926 |
| drop | #2927 |
| cgvhd | #2929 |
| surgery 2 | #2932 |
| eye diseases | #2940 |
| interleukin8 il8 | #2953 |
| endophthalmitis | #2955 |
| refraction ocular | #2961 |
| excision | #2987 |
| inter rater | #3000 |
| eosinophils humans | #3014 |
| measured elisa | #3014 |
| normal eyes | #3037 |
| cultured chemokines | #3051 |
| agents interferon | #3054 |
| protease activated | #3059 |
| staining labeling | #3068 |
| safety assessed | #3072 |
| evaporation | #3080 |
| aged anti | #3083 |
| treatment total | #3085 |
| immunologic receptors | #3118 |
| baseline month | #3124 |
| rtpcr | #3132 |
| expression adhesion | #3132 |
| dermatitis | #3150 |
| vehicle | #3153 |
| cells graft | #3163 |
| susceptibility humans | #3175 |
| symptom scores | #3181 |
| cell count | #3181 |
| methods seventy | #3188 |
| 10 patients | #3190 |
| investigate efficacy | #3197 |
| recruited study | #3208 |
| sjogren syndrome | #3228 |
| study medication | #3240 |
| patient global | #3249 |
| cell densities | #3269 |
| accommodation | #3274 |
| acuity | #3280 |
| meniscus | #3289 |
| variance case | #3295 |
| interferometry | #3299 |
| normal control subjects | #3302 |
| intraoperative male | #3322 |
| allergens | #3325 |
| cells assessed | #3332 |
| subjective | #3340 |
| efficacy anti | #3343 |
| diclofenac sodium | #3345 |
| dressings | #3352 |
| histamine receptor | #3356 |
| cellular level | #3367 |
| pfu | #3369 |
| diabetic patients | #3375 |
| fibroblast proliferation | #3377 |
| coherence tomography | #3398 |
| ova | #3409 |
| instillation | #3411 |
| normal subjects | #3415 |
| air pollutants | #3416 |
| alpha cell | #3440 |
| patients obstructive | #3460 |
| host disease humans | #3469 |
| papilla | #3493 |
| cataract | #3514 |
| local excision | #3555 |
| interleukin8 male | #3570 |
| visual analog | #3572 |
| agents steroidal | #3585 |
| sjogren | #3591 |
| tokyo | #3609 |
| immunoglobulin ige | #3614 |
| signs | #3617 |
| agents incidence | #3623 |
| plaque formation | #3626 |
| weeks surgery | #3640 |
| method enzyme | #3648 |
| pressure male | #3653 |
| cell density | #3654 |
| fiftytwo patients | #3661 |
| adult chronic | #3668 |
| disease adolescent | #3694 |
| vegf mrna | #3694 |
| 016 ± | #3698 |
| cytological | #3709 |
| 29 years | #3711 |
| gels humans | #3720 |
| week 1 | #3745 |
| adult air | #3751 |
| suture techniques | #3751 |
| signs symptoms | #3758 |
| pm25 | #3770 |
| situ nickend | #3772 |
| management disease | #3773 |
| helper type | #3773 |
| anterior segment | #3782 |
| hydrochloride | #3792 |
| lenses | #3815 |
| docosahexaenoic acid dha | #3823 |
| perennial | #3824 |
| patients examined | #3835 |
| amniotic | #3843 |
| studies severity | #3851 |
| intercellular adhesion molecule | #3865 |
| interleukin13 | #3866 |
| strabismus | #3900 |
| diseases study | #3906 |
| complications observed | #3914 |
| mann | #3916 |
| interleukin2 interleukin4 | #3949 |
| specific ige | #3951 |
| subjects included | #3968 |
| cell expression | #3989 |
| microscopy | #3992 |
| chemokines | #3992 |
| discontinued treatment | #3993 |
| break | #3994 |
| lower compared | #3996 |
| studies roc | #3998 |
| ulcer | #4009 |
| cells hla | #4035 |
| female flow | #4036 |
| echinocandins | #4040 |
| acrylic resins | #4047 |
| immunosuppressive | #4068 |
| readings | #4071 |
| steroid | #4091 |
| subjects methods | #4093 |
| steroid treatment | #4095 |
| acinar | #4097 |
| discontinue | #4100 |
| inflammatory disorders | #4103 |
| tended higher | #4106 |
| ige | #4116 |
| bronchial asthma | #4135 |
| th2 | #4137 |
| severe effects | #4168 |
| female glaucoma | #4179 |
| aged sensitivity | #4189 |
| papillary | #4193 |
| α induced | #4193 |
| male surveys | #4211 |
| measured enzyme | #4218 |
| percentages | #4223 |
| visual acuity | #4239 |
| gamma interleukin1 | #4281 |
| heidelberg | #4286 |
| adult antibody | #4327 |
| purpose report | #4328 |
| clinically diagnosed | #4349 |
| visual function | #4360 |
| edema | #4368 |
| effective improving | #4382 |
| 11 patients | #4410 |
| reaction rna | #4417 |
| infiltrates | #4459 |
| interleukin | #4482 |
| healed | #4489 |
| conclusions clinical | #4503 |
| studies environmental | #4513 |
| scores | #4515 |
| gamma interleukin4 | #4530 |
| 14 28 | #4549 |
| baseline 2 | #4575 |
| excimer | #4592 |
| viral respiratory | #4601 |
| surface reconstruction | #4608 |
| blinding | #4654 |
| years recruited | #4660 |
| lid | #4671 |
| cytometric | #4683 |
| studies prosthesis | #4704 |
| patients bilateral | #4711 |
| chemotactic | #4713 |
| treatment conclusions | #4714 |
| 4 9 | #4720 |
| tomography optical | #4729 |
| immunoenzyme | #4748 |
| dermatitis contact | #4754 |
| 36 years | #4755 |
| 80 child | #4790 |
| glaucoma patients | #4793 |
| purpose assess | #4807 |
| healthy control subjects | #4826 |
| patients administration | #4833 |
| 111 patients | #4837 |
| immunoenzyme techniques | #4857 |
| protein array | #4864 |
| allergy | #4868 |
| fluoresceins fluorescent | #4892 |
| adult biological | #4902 |
| chronic gvhd | #4913 |
| foreign body | #4922 |
| defensins | #4929 |
| infrared rays | #4946 |
| scale 0 | #4948 |
| logarithm | #4974 |
| lower density | #5019 |
| months treatment | #5023 |
| nitrogen dioxide | #5023 |
| optical coherence | #5029 |
| groups compared | #5036 |
| opacities | #5052 |
| enterotoxins | #5054 |
| safety treatment | #5056 |
| unpaired | #5095 |
| amnion | #5097 |
| induced male | #5101 |
| strip | #5103 |
| lipopeptides | #5119 |
| glaucoma | #5131 |
| purposewe | #5143 |
| receptors chemokine | #5174 |
| patients 100 | #5189 |
| steroids | #5194 |
| epithelium | #5224 |
| thirtysix patients | #5224 |
| observed 2 | #5246 |
| determine efficacy | #5268 |
| lysine male | #5269 |
| child combined | #5301 |
| analysis reverse | #5302 |
| 2 weeks | #5303 |
| enzyme linked | #5314 |
| time measurements | #5318 |
| 74 years | #5320 |
| humans hyperthermia | #5365 |
| imidazoles male | #5366 |
| 20 25 | #5367 |
| allergen | #5403 |
| metaplasia | #5404 |
| agents chronic | #5423 |
| factors visual | #5431 |
| procedures postoperative | #5475 |
| differential disease | #5487 |
| igg anti | #5508 |
| keratitis | #5509 |
| alum | #5527 |
| mucin1 | #5530 |
| treatment follow | #5537 |
| barr virus | #5547 |
| humans lasers | #5560 |
| epithelial barrier | #5584 |
| counted | #5606 |
| visual analog scale | #5621 |
| spearman correlation | #5634 |
| aims evaluate | #5656 |
| giant | #5659 |
| publication administration | #5662 |
| il13 | #5676 |
| sutures | #5684 |
| eye proteins | #5692 |
| opacity | #5697 |
| histamine antagonists | #5721 |
| tonometry | #5735 |
| techniques cells | #5746 |
| th2 cells | #5747 |
| grades | #5747 |
| adult cell | #5754 |
| 889 | #5801 |
| male time | #5839 |
| tgfbeta1 | #5853 |
| sickness impact | #5861 |
| icam1 | #5871 |
| agents candida | #5881 |
| score 3 | #5903 |
| biomarkers case | #5924 |
| expression alpha | #5963 |
| nsaid | #5969 |
| antibody anti | #5999 |
| microscopy study | #6002 |
| chemotactic factors | #6005 |
| ip10 | #6027 |
| adverse health effects | #6035 |
| rhinitis allergic | #6041 |
| humans hyaluronic | #6046 |
| higher compared | #6074 |
| exacerbate | #6114 |
| controlled clinical | #6123 |
| baseline 1 | #6145 |
| placebo treatment | #6146 |
| thickening | #6158 |
| male neutrophils | #6171 |
| patients refractory | #6181 |
| treatment adverse | #6199 |
| desiccation | #6204 |
| resultsthe | #6224 |
| genetic adolescent | #6226 |
| diagnostic techniques | #6234 |
| efficacy | #6247 |
| impact profile | #6258 |
| subjects randomized | #6267 |
| johnson | #6274 |
| steroidal | #6295 |
| cells lymphocytes | #6296 |
| patients control | #6337 |
| dosed | #6343 |
| allergies | #6348 |
| ocular hypertension | #6376 |
| 005 conclusion | #6428 |
| ulceration | #6435 |
| japan male | #6443 |
| asthmatic agents | #6445 |
| wearing | #6466 |
| 2 groups | #6475 |
| air pollution | #6514 |
| house dust | #6543 |
| rejection humans | #6543 |
| primary human | #6559 |
| diclofenac | #6566 |
| 3 groups | #6582 |
| anti asthmatic | #6611 |
| glucocorticoids humans | #6618 |
| linked immunosorbent | #6618 |
| 3 months | #6643 |
| conventional therapy | #6652 |
| immunosorbent assay | #6675 |
| months compared | #6704 |
| humans japan | #6704 |
| inflammatory | #6764 |
| chemokine | #6774 |
| graded | #6779 |
| breakup | #6780 |
| severe | #6799 |
| serum total | #6811 |
| 1 14 | #6842 |
| male microscopy | #6859 |
| treatment refractory | #6864 |
| bcva | #6877 |
| enzymelinked immunosorbent assay | #6904 |
| conventional treatment | #6981 |
| wear | #7013 |
| adhesion molecules | #7016 |
| years treated | #7049 |
| contrast sensitivity | #7060 |
| observed treatment | #7063 |
| humans hypothermia | #7079 |
| 6 patients | #7102 |
| epsteinbarr virus | #7188 |
| transplantation child | #7270 |
| patients 9 | #7284 |
| water loss | #7310 |
| infections herpesvirus | #7328 |
| viral female | #7329 |
| treatment period | #7342 |
| syndromes | #7375 |
| photography | #7394 |
| severity | #7473 |
| relief | #7481 |
| seasonal | #7483 |
| alpha regulation | #7520 |
| confocal microscopy | #7575 |
| epithelial | #7618 |
| humans immunoglobulin | #7674 |
| inflammatory agents | #7677 |
| autumn | #7680 |
| treatment decreased | #7714 |
| calcineurin inhibitors | #7727 |
| 16 patients | #7794 |
| hyperthermia induced | #7892 |
| cyclosporine | #7933 |
| epstein barr | #8024 |
| steroidal anti | #8072 |
| tnfalpha | #8140 |
| methods fifty | #8160 |
| fk506 | #8206 |
| aged minimally | #8301 |
| barr | #8314 |
| production human | #8367 |
| assess safety | #8419 |
| evaluate effectiveness | #8448 |
| purpose | #8455 |
| patients normal | #8497 |
| regulation vascular | #8551 |
| statistically differences | #8556 |
| hypothermia induced | #8648 |
| graft rejection | #8670 |
| hladr | #8682 |
| corticosteroid | #8683 |
| epithelial cells | #8827 |
| score 1 | #8860 |
| design prospective | #8861 |
| year male | #8873 |
| ceramides | #8893 |
| capsular | #8909 |
| ovalbumin | #8972 |
| silicone | #8991 |
| anti inflammatory | #9041 |
| surgical flaps | #9087 |
| complaints | #9098 |
| 3 6 | #9098 |
| illness adolescent | #9141 |
| immunosorbent | #9162 |
| humidity | #9176 |
| cutoff values | #9181 |
| patients 16 | #9191 |
| 4 12 | #9193 |
| treatment adolescent | #9195 |
| 0 3 | #9331 |
| wilcoxon | #9408 |
| 375 | #9414 |
| virus ebv | #9435 |
| 8 patients | #9463 |
| humans intraoperative | #9556 |
| hypersensitivity | #9569 |
| reaction tumor | #9638 |
| adult anti | #9709 |
| particulate matter | #9803 |
| superficial | #9826 |
| refraction | #9835 |
| methods prospective | #9836 |
| anesthetics local | #9840 |
| limbic | #9855 |
| fluorescent dyes | #9935 |
| term treatment | #10001 |
| objectively | #10055 |
| postoperatively | #10097 |
| technique indirect | #10132 |
| symptoms patients | #10143 |
| 1year followup | #10154 |
| 10 minutes | #10161 |
| foreign | #10171 |
| factor vegf | #10178 |
| biomarkers child | #10229 |
| antigens humans | #10284 |
| compared treatment | #10317 |
| rhinitis | #10337 |
| glands | #10364 |
| cytokines | #10378 |
| week 4 | #10414 |
| common complication | #10417 |
| questionnaire | #10420 |
| shortterm | #10427 |
| mast cells | #10496 |
| lens | #10588 |
| subjects age | #10599 |
| longterm treatment | #10644 |
| chamber | #10647 |
| male prospective | #10703 |
| volunteers | #10707 |
| substance | #10715 |
| compared controls | #10729 |
| nsaids | #10777 |
| cells th2 | #10778 |
| filtering | #10900 |
| metabolism male | #10953 |
| il5 | #11022 |
| examinations | #11187 |
| patient demographics | #11192 |
| 20 40 | #11212 |
| body temperature | #11219 |
| complications retrospective | #11251 |
| eczema | #11287 |
| patients 4 | #11337 |
| purposeto | #11381 |
| nonsteroidal | #11393 |
| corrected | #11394 |
| mast | #11549 |
| interleukin8 | #11599 |
| eosinophilic | #11723 |
| adjunctive | #11730 |
| receptors immunologic | #11956 |
| longterm outcomes | #12069 |
| evaluate | #12086 |
| grading | #12107 |
| coherence | #12125 |
| prospective | #12163 |
| 0001 conclusions | #12216 |
| csa | #12259 |
| asthmatic | #12282 |
| sickness | #12312 |
| tnf α | #12395 |
| thirty | #12576 |
| volunteers humans | #12586 |
| evaluate effects | #12612 |
| elisa | #12717 |
| mucous | #12766 |
| tnfα | #12781 |
| agents anti | #12822 |
| evaluate safety | #12879 |
| host disease | #12922 |
| seconds | #13199 |
| minutes | #13216 |
| complications diabetes | #13262 |
| epithelia | #13267 |
| 4 weeks | #13267 |
| 005 | #13326 |
| tests performed | #13356 |
| 1 3 | #13413 |
| 2 cases | #13447 |
| underwent | #13549 |
| western blot analysis | #13578 |
| prosthesis design | #13600 |
| cultured coculture | #13613 |
| particulate | #13632 |
| clinical examination | #13829 |
| life surveys | #13937 |
| mast cell | #13997 |
| study clinical | #14017 |
| dogs female | #14046 |
| graft host | #14084 |
| 60 patients | #14391 |
| myopia | #14577 |
| diseases diabetes | #14729 |
| vascular cell | #14846 |
| spearman | #14877 |
| implantation | #14889 |
| infections staphylococcus | #15065 |
| hyaluronic | #15111 |
| allograft | #15158 |
| patients follow | #15344 |
| visual | #15382 |
| refractory | #15389 |
| burning | #15485 |
| discontinued | #15495 |
| 1 2 | #15658 |
| longterm | #15717 |
| 006 | #15839 |
| graft | #15913 |
| tnf alpha | #16084 |
| radiation injuries | #16251 |
| patients divided | #16456 |
| 32 patients | #16659 |
| 15 patients | #16684 |
| adhesion molecule1 | #16940 |
| herpesvirus 4 | #16966 |
| evaluate efficacy | #17035 |
| 4 human | #17084 |
| patients assigned | #17274 |
| noninvasive | #17324 |
| molecule1 | #17435 |
| antibiotics antineoplastic | #17587 |
| histopathologic | #17743 |
| acid male | #17891 |
| method female | #17912 |
| anterior | #17986 |
| symptoms | #18008 |
| inflammation | #18029 |
| healthy | #18209 |
| morphologic | #18280 |
| stained | #18391 |
| alkylating | #18391 |
| vegf | #18469 |
| 0001 | #18534 |
| cold temperature | #18622 |
| 00001 | #18681 |
| 9 patients | #18689 |
| neovascularization | #19381 |
| female fluorescent | #19461 |
| stromal | #19499 |
| aged postoperative | #19510 |
| lipids male | #19666 |
| endothelial growth | #19723 |
| nerve fibers | #19872 |
| follow period | #19917 |
| artificial | #20012 |
| female graft | #20067 |
| 24 patients | #20143 |
| count cell | #20148 |
| epithelial cell | #20437 |
| complications prospective | #20558 |
| patients evaluated | #20800 |
| 22 patients | #21524 |
| 003 | #21648 |
| daily | #22391 |
| gland | #22647 |
| followup period | #22674 |
| male middle aged | #22802 |
| ifngamma | #23824 |
| outcome measures | #24510 |
| enrolled | #24838 |
| transplantation homologous | #25557 |
| patients adolescent | #25760 |
| adult body | #25783 |
| adult analysis | #26261 |
| conclusions patients | #26516 |
| adult biomarkers | #29382 |
| statistically | #29861 |
| age matched | #29948 |
| humans inflammation | #30660 |
| cells female | #31500 |
レポートを実行します | |
Prominent publications by Hiroshi Fujishima
KOL-Index: 19369
PURPOSE: To describe MUC5AC alterations and the ocular surface disorder in atopic patients with or without corneal ulcers.
METHODS: Atopic patients' eyes were divided into two groups according to the presence and absence of corneal ulceration. The subjects underwent corneal sensitivity measurements, Schirmer test, tear film break-up time (BUT), fluorescein and Rose Bengal staining of the ocular surface and conjunctival impression cytology and brush cytology. Impression cytology samples ...
| で知られている Ocular Surface | Eyes Corneal Ulcers | Atopic Patients | Brush Cytology | Akc Vkc |
Application of Visante Optical Coherence Tomography Tear Meniscus Height Measurement in the Diagnosis of Dry Eye Disease
[ PUBLICATION ]
PURPOSE: To investigate the applicability of tear meniscus height (TMH) measurement using Visante optical coherence tomography (OCT) in the diagnosis of dry eye disease.
DESIGN: Prospective, controlled, single-center study.
PARTICIPANTS: Twenty-four right eyes of 24 patients (6 males, 18 females; mean age, 63.14±13.4 years) with definite dry eye according to the Japanese dry eye diagnostic criteria and 27 right eyes of 27 control subjects (12 males, 15 females; mean age, 56.04±14.22 ...
| で知られている Dry Eye Disease | Coherence Tomography | Tear Meniscus Height | Sensitivity Specificity | Strip Meniscometry |
Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
[ PUBLICATION ]
BACKGROUND: Although the oxidative stress status in atopic skin disease has been reported to be elevated, there are still no studies related to the status of oxidative stress in atopic ocular surface disease. The purpose of this study was to evaluate the ocular surface lipid oxidative stress status and inflammation in atopic keratoconjunctivitis (AKC) patients and normal subjects.
METHODS: Twenty eight eyes of 14 patients (9 males, 5 females) with AKC and 18 eyes of 9 age and sex matched ...
| で知られている Oxidative Stress | Akc Patients | Surface Disease | Inflammatory Cells | 5 Females |
KOL-Index: 11411
PURPOSE: To evaluate the effectiveness and safety of a novel cyclosporine 0.1% aqueous ophthalmic solution in a large population with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
METHODS: A prospective observational postmarketing study was initiated in Japan. A total of 594 patients with VKC or AKC were started on this drug within 1 year after market launch (January 2006) and completed a 6-month follow-up. These patients were observed clinically, and ...
| で知られている Vkc Akc | Allergic Conjunctivitis | Topical Steroids | 1 Month | Objective Signs |
Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface at cellular level in the conjunctiva and the cornea may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate the MUC16 and MUC5AC alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis (AKC).
METHODS: Thirty-six eyes of 18 AKC patients as well as 28 eyes of 14 age- and ...
| で知られている Atopic Keratoconjunctivitis | Ocular Surface | Patients Akc | Muc5ac Muc16 | Goblet Cell |
KOL-Index: 10572
BACKGROUND: The pathogenesis of the ocular surface disease in atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) has not been fully understood. We tried to clarify the differences in the ocular surface status in patients with AKC, VKC, and healthy control subjects.
METHODS: Twenty-four eyes of 12 AKC patients, 12 eyes of six VKC patients, and 20 eyes of 10 normal control subjects were studied. The subjects underwent corneal sensitivity measurements, Schirmer test, ...
| で知られている Ocular Surface | Atopic Keratoconjunctivitis | Patients Akc | Eyes Vkc | Brush Cytology |
Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface alterations at the cellular level in the conjunctiva and the cornea, may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate MUC 1, 2 and 4 alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis.
METHODS: Twenty-eight eyes of 14 atopic keratoconjunctivitis patients as well as ...
| で知られている Atopic Keratoconjunctivitis | Ocular Surface | Brush Cytology | Corneal Sensitivity | Epithelial Mucins |
KOL-Index: 10372
PURPOSE: To prospectively assess the clinical outcome after implantation of the 1CU accommodating intraocular lens (IOL) and a foldable acrylic IOL (AcrySof, Alcon).
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa Hospital, Ichikawa, and Minami Aoyama Eye Clinics, Tokyo, Yokohama, Japan.
METHODS: Twenty-two eyes of 16 patients with cataract had phacoemulsification implantation of 1CU accommodating IOL. Twenty eyes of 10 age-matched and sex-matched patients with ...
| で知られている Intraocular Lens | Visual Acuity | 1cu Iol | Cataract Surgery | Amplitude Accommodation |
KOL-Index: 10324
PURPOSE: Eosinophils are known to have important roles in the pathogenesis of allergic conjunctivitis. Prostaglandin (PG) D2, which has been implicated as a factor in allergic diseases, is known to have chemotactic activity for eosinophils. Its receptor, chemoattractant receptor homologous molecule expressed on TH2 (CRTH2), serves as a receptor for PGD2 and has been reported to mediate PGD2-dependent migration of eosinophils. In the present study, both eosinophil toxic activity for ...
| で知られている Receptor Crth2 | Chemotaxis Eosinophils | Allergic Conjunctivitis | Pgd2dependent Migration | Homologous Molecule |
A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis
[ PUBLICATION ]
AIMS: To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
METHODS: This was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of ...
| で知られている Severe Allergic Conjunctivitis | Tacrolimus Ophthalmic | Objective Signs | Corneal Involvement | Clinical Trial |
TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts
[ PUBLICATION ]
Giant papillary formation containing newly formed vessels is a major characteristic of severe allergic conjunctivitis, such as atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC). We examined production of vascular endothelial growth factor (VEGF) from cultured conjunctival fibroblasts from normal volunteers under stimulation with type 1-, type 2-helper T cell derived and proinflammatory cytokines to investigate the mechanism of giant papillae formation in AKC/VKC. ...
| で知られている Conjunctival Fibroblasts | Vascular Endothelial | Growth Factor | Vegf Concentration | Akc Vkc |
KOL-Index: 9650
PURPOSE: To prospectively assess the clinical and visual outcomes of phacoemulsification and implantation of a rollable intraocular lens (IOL) with a thin optic and compare the results with those of implantation of a foldable acrylic IOL.
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Chiba, Japan.
METHODS: Sixteen consecutive eyes of 8 patients (4 women, 4 men) with corticonuclear cataract had small-incision clear corneal ...
| で知られている Intraocular Lens | Thinoptx Iol | Phacoemulsification Implantation | Visual Acuity | 6 Months |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease
[ PUBLICATION ]
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. ...
| で知られている Ocular Surface | Topical Cyclosporine | Eye Patients | Chronic Graft | Host Disease |
Measurement of IL‐4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis
[ PUBLICATION ]
To elucidate the mechanism of ocular surface allergic disease, we focused on IL-4, which is one of the key factors in regulating IgE production, and thus determined the concentration of IL-4 in tears. IL-4 concentration was determined in the tears of 15 patients with seasonal allergic conjunctivitis, 15 vernal keratoconjunctivitis (VKC), 10 giant papillary conjunctivitis (GPC), 10 patients with non-allergic conjunctivitis and post-cataract surgical conjunctivitis as intermediate ...
| で知られている Allergic Conjunctivitis | Tears Patients | Vkc Gpc | Normal Controls | Linked Immunosorbent |
のための重要な人々 Allergic Conjunctivitis
世界のトップコル
Hiroshi Fujishima:専門家の影響
その概念Hiroshi Fujishima直接的な影響があります:Allergic conjunctivitis, Dry eye, Atopic keratoconjunctivitis, Conjunctival fibroblasts, Allergic conjunctival disease, Brush cytology, Ocular surface, Vernal keratoconjunctivitis.
Hiroshi Fujishima:KOLインパクト
他の著者の仕事に関連する概念for which Hiroshi Fujishima 影響力があります:Dry eye, Ocular surface, Allergic conjunctivitis, Tear film, Amniotic membrane, Cataract surgery, Contact lens.
Tools
これはあなたのプロフィールですか？ あなたのプロフィールを主張します URLをコピーします プロフィールへのリンクを埋め込みます |